Terminal2 — Card #00: [Diagnosis Name]

S01 Everyone

What Is It

Definition, mechanism, and the clinical reality of this diagnosis at end of life. What the hospice team needs to understand on day one.

US Cardiomyopathy Prevalence

~1 in 500

~1 in 500 Americans have some form of cardiomyopathy; dilated cardiomyopathy accounts for ~60% of non-ischemic cardiomyopathy.^[1]

LVAD Implants/Year

4,000–5,000

~4,000–5,000 LVADs implanted annually in the US — the majority now as destination therapy rather than bridge to transplant.^[2]

Heart Transplants/Year

~3,500

~3,500 — the only cure; demand vastly exceeds supply; the average wait time is 2–3 years, meaning many patients on the list will die waiting.^[3]

ATTR-CM Underdiagnosis

~1 in 10

ATTR-CM is estimated to affect 1 in 10 older adults with HFpEF — the vast majority are never diagnosed; tafamidis approval in 2019 changed the clinical urgency of diagnosis.^[4]

Cardiomyopathy is disease of the heart muscle itself — not a consequence of blocked coronary arteries or valve failure, but a primary failure of the myocardium to contract, relax, or conduct normally. The major subtypes — dilated (DCM), hypertrophic (HCM), restrictive (including cardiac amyloidosis), and arrhythmogenic — each follow distinct pathophysiologic trajectories, but they converge at the same clinical destination: a heart that can no longer sustain the body's metabolic demands despite maximum medical and device therapy. End-stage cardiomyopathy is defined by the exhaustion of all medical, device, and surgical options — or, equally important, by a patient's informed decision to stop pursuing them. The ACC/AHA Stage D designation captures this: refractory symptoms at rest despite guideline-directed medical therapy (GDMT), inotropic dependence, recurrent hospitalizations, or consideration for advanced therapies like left ventricular assist devices (LVADs) or transplant.^[1]^[5]

What makes cardiomyopathy unique in hospice is the technology. The LVAD that may be sustaining the patient's life requires daily driveline site care, controller monitoring, battery exchanges every 10–14 hours, and INR management for continuous anticoagulation. This exceeds the technical demands of any other home hospice device — including home ventilators and peritoneal dialysis. The decision to deactivate that LVAD — to allow the heart to fail without mechanical support — is one of the most ethically complex decisions in medicine, carrying the emotional weight of "turning off the machine that keeps them alive" even though it is ethically and legally equivalent to withdrawing any life-sustaining therapy. And the patient who was told a transplant was possible, who lived for months or years on the waitlist enduring repeated right heart catheterizations and panel-reactive antibody monitoring, and was then delisted due to progressive decline or new comorbidity, carries a grief that the hospice team must meet with specific acknowledgment — not generic platitudes about "being at peace," but direct recognition that something concrete and hoped-for was taken away.^[2]^[6]

The hospice team must also understand that cardiomyopathy trajectories are fundamentally unpredictable compared to cancer. Heart failure patients follow a pattern of repeated acute exacerbations with partial recovery — a sawtooth decline — that makes prognosis notoriously difficult. A patient who appears to be days from death may rally dramatically with IV diuresis and survive weeks or months. This unpredictability is distressing for families, confusing for new clinicians, and is a primary reason heart failure patients are referred to hospice far later than they should be. The median hospice length of stay for heart failure remains under 3 weeks — a systemic failure of timely referral.^[7]

🧭 Clinical framing

Cardiomyopathy at end of life means managing the technology — the LVAD, the ICD, the telemetry monitors, the continuous infusion pumps — as much as managing the disease itself. The patient's home may look like a cardiac ICU: a controller clipped to the belt, a driveline tunneled through the abdominal wall, battery chargers plugged in beside the bed, and an alarm protocol sheet taped to the refrigerator. The hospice team is not just managing heart failure symptoms — they are managing a life that has been lived inside a medical system for years, and a family that has been trained to respond to alarms, check INR values, and fear every controller beep. Every visit begins with the technology, because the technology is what stands between the patient and death.

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"The first time you walk into an LVAD patient's home, it hits different. There's a controller on the belt with a cable running under their shirt into their abdomen. There's a driveline exit site that needs sterile dressing changes. There's a battery charger on the nightstand and a backup controller in a bag by the door. There's an alarm protocol on the refrigerator — the family has it memorized. They know what each beep means. They've been doing this for months, sometimes years. And now you're there to have the conversation about turning it off. You're asking a wife to agree to silence the machine that she has been charging, monitoring, and listening to every night — the machine that she believes is keeping her husband alive. Because it is. You don't rush that conversation. You don't have it on the first visit. You earn the right to have it by learning the machine first — by showing them you understand what they've been carrying. Then, when the time comes, you sit with them and you say: 'This is your decision. There is no wrong answer. But I need you to know what will happen, step by step, so there are no surprises.' And you plan it like the most important clinical event of your career. Because it is."

— Waldo, NP · Terminal2

S02 Clinician

How It's Diagnosed

Diagnostic workup, staging, and what to look for in hospice records. Most patients arrive with an established diagnosis — this section helps you read it.

Diagnostic Workup

Echocardiogram: The cornerstone — dilated LV with reduced EF (<40%) for DCM; asymmetric septal hypertrophy with or without LVOT obstruction and SAM of the mitral valve for HCM; small stiff ventricles with biatrial enlargement and diastolic dysfunction for restrictive CMP; granular sparkling myocardial texture with biatrial enlargement and thickened walls for cardiac amyloidosis^[1]
Cardiac MRI: Late gadolinium enhancement (LGE) patterns — midwall LGE in DCM (prognostic for arrhythmia risk), patchy LGE in HCM, diffuse subendocardial or transmural LGE in amyloidosis, native T1 mapping and ECV for amyloid burden quantification^[8]
Right heart catheterization: PCWP (elevated >18 mmHg), cardiac output/cardiac index (CI <2.0 L/min/m² defines Stage D hemodynamics), pulmonary vascular resistance (PVR — critical for transplant candidacy), transpulmonary gradient^[5]
Endomyocardial biopsy: Gold standard for infiltrative diseases — Congo red staining for amyloid (apple-green birefringence), immunohistochemistry to distinguish ATTR from AL, giant cell myocarditis, sarcoidosis (non-caseating granulomas)^[9]
Genetic testing: TTN truncating variants (~25% of DCM), LMNA (DCM with high arrhythmia/sudden death risk — critical for family screening), MYH7 and MYBPC3 (HCM), SCN5A (DCM with conduction disease), TTR gene sequencing (hereditary ATTR-CM)^[10]
Pyrophosphate scintigraphy (Tc-99m PYP scan): Non-invasive diagnosis of ATTR-CM — Grade 2–3 uptake with negative serum/urine immunofixation confirms ATTR without biopsy; transformed the diagnostic pathway for cardiac amyloidosis since 2016^[11]
Serum/urine immunofixation with free light chains: Mandatory screening to exclude AL amyloidosis before attributing cardiac amyloid to ATTR — AL requires urgent hematology/oncology referral for chemotherapy^[9]
NT-proBNP and troponin: Staging biomarkers in cardiac amyloidosis (Mayo staging system for AL; UK National Amyloidosis Centre staging for ATTR); also prognostic in DCM and HCM; serial trending guides therapy response^[12]

What to Look for in Hospice Records

LVAD presence: Device type (HeartMate 3 is current standard; HeartMate II axial-flow still in the field; HVAD was discontinued by Medtronic in June 2021 due to neurologic adverse events — urgent if still implanted), implant date, indication (BTT = bridge to transplant, DT = destination therapy, BTC = bridge to candidacy), current speed/flow/pulsatility index (PI) settings^[2]
ICD presence and programming: Single-chamber vs. biventricular (CRT-D), shock zone settings, whether anti-tachycardia pacing (ATP) is active — critical for deactivation planning^[13]
Transplant status: Active on the list, delisted (document reason — new contraindication, progressive decline, patient choice), or never listed (document why — age, comorbidities, psychosocial, PVR too high)^[3]
Cardiomyopathy subtype: DCM, HCM (obstructive vs. non-obstructive), restrictive, ATTR-CM (wild-type vs. hereditary — specify variant), AL amyloid, arrhythmogenic RV cardiomyopathy, peripartum — each has distinct management implications
EF at last echocardiogram: Baseline and trend — note that EF is often misleadingly "normal" in HCM and amyloidosis despite severe disease; GLS (global longitudinal strain) is more sensitive
Hemodynamic data from last right heart catheterization: CI, PCWP, PA pressures, PVR — these define the severity of the hemodynamic failure and guide inotrope/diuretic decisions^[5]
Genetic testing results: Especially LMNA (family screening urgent), TTR variant (Val122Ile in ~3–4% of Black Americans), TTN (reassuring — lower arrhythmia risk than LMNA)^[10]
ATTR-CM tafamidis status: Is the patient on tafamidis 61 mg daily? If so, continue — this is one of the clearest examples of targeted therapy continuation in hospice^[4]
Current GDMT regimen and tolerability: ARNI/ACEi/ARB, beta-blocker (carvedilol, metoprolol succinate, bisoprolol), MRA (spironolactone/eplerenone), SGLT2i (dapagliflozin/empagliflozin) — document doses, tolerability, recent changes^[5]
INR management for LVAD patients: Target INR typically 2.0–3.0 for HeartMate 3; frequency of monitoring; bridging strategy; history of bleeding or thrombotic complications^[2]
Driveline infection history: Active or prior driveline site infections — these are the leading infectious complication of LVADs and can become the primary driver of morbidity and mortality; document organisms, treatment history, current dressing protocol^[14]

💡 For families

💡 Para las familias

By the time your loved one has enrolled in hospice, the diagnostic workup is complete. Your family member has been through extensive testing — echocardiograms, cardiac MRIs, catheterizations, bloodwork, and possibly genetic testing. The hospice team reviews all of these results to understand exactly where your loved one is in their heart disease. No new invasive testing is needed now. The focus shifts entirely to comfort, symptom management, and supporting your family through what comes next.

Cuando su ser querido se inscribe en hospicio, el proceso de diagnóstico ya está completo. El equipo de hospicio revisa todos los resultados para comprender exactamente la condición del corazón. No se necesitan nuevas pruebas invasivas. El enfoque ahora es completamente en la comodidad y el apoyo a su familia.

S03 Everyone

Causes & Risk Factors

Modifiable and hereditary risk factors. Relevant for family conversations, genetic counseling referrals, and answering "why did this happen?"

Dilated Cardiomyopathy (DCM)

Idiopathic (~50%): No identifiable cause despite full workup — historically labeled "idiopathic," though many of these likely harbor unidentified genetic variants; represents the largest single category of DCM^[1]
Familial/Genetic (~30–40%): TTN truncating variants (titin — most common genetic cause, ~25% of familial DCM, generally lower arrhythmia risk), LMNA (lamin A/C — aggressive phenotype with high risk of sudden cardiac death, AV block, and need for ICD; mandate family screening), SCN5A (sodium channel — DCM with conduction disease), MYH7 and TNNT2 (sarcomeric — overlap with HCM genetics)^[10]
Viral myocarditis: Post-viral inflammatory cardiomyopathy — Coxsackie B, adenovirus, parvovirus B19, HHV-6, HIV, SARS-CoV-2; acute myocarditis → chronic inflammatory DCM in a subset; endomyocardial biopsy may show persistent viral genome^[15]
Cardiotoxic exposures: Anthracyclines (doxorubicin — cumulative dose-dependent, risk increases sharply above 400 mg/m²), trastuzumab (reversible if caught early), immune checkpoint inhibitors (fulminant myocarditis — rare but high mortality), radiation therapy to the mediastinum^[16]
Alcohol: Chronic heavy use (>7–8 drinks/day for >5 years) — partially reversible with abstinence; one of the few modifiable causes; EF may improve 10–15% with cessation^[1]
Peripartum cardiomyopathy: Onset in the last month of pregnancy or within 5 months postpartum; affects ~1 in 1,000–4,000 live births; ~50% recover EF fully; the remainder progress to end-stage; subsequent pregnancies carry recurrence risk^[17]
Tachycardia-induced: Sustained tachyarrhythmias (atrial fibrillation, SVT) causing ventricular dysfunction — often reversible if rate/rhythm is controlled; must be excluded before labeling DCM as idiopathic
Sarcoidosis: Granulomatous infiltration of the myocardium — may cause DCM, conduction disease, or ventricular arrhythmias; cardiac involvement in up to 25% of systemic sarcoidosis; diagnosed by cardiac MRI (patchy LGE) or biopsy^[18]

Hypertrophic, Restrictive & Cardiac Amyloidosis

Hypertrophic cardiomyopathy (HCM): Genetic in ~60% — MYH7 (beta-myosin heavy chain) and MYBPC3 (myosin-binding protein C) account for the majority; autosomal dominant with variable penetrance; most common cause of sudden cardiac death in young athletes; end-stage "burned-out" HCM occurs in 5–10% — the hypertrophied ventricle thins, dilates, and EF drops below 50%, resembling DCM with particularly poor prognosis^[19]
ATTR cardiac amyloidosis — wild-type (ATTRwt): Age-related misfolding of normal transthyretin protein; predominantly affects men over age 65; found in up to 13% of HFpEF patients over 60 and 16% of patients undergoing TAVR; massively underdiagnosed; tafamidis 61 mg daily reduces mortality (ATTR-ACT trial)^[4]
ATTR cardiac amyloidosis — hereditary (ATTRv): Val122Ile (V122I) variant present in ~3–4% of Black Americans (~1.5 million carriers); causes restrictive cardiomyopathy typically after age 60; all first-degree relatives should be offered TTR gene testing; tafamidis is equally effective^[20]
AL (light-chain) amyloidosis: Clonal plasma cell disorder producing misfolded immunoglobulin light chains that deposit in the heart; requires urgent chemotherapy (bortezomib-based) or autologous stem cell transplant; much worse untreated prognosis than ATTR — median survival 6 months without treatment when cardiac involvement is present; must be excluded before diagnosing ATTR^[9]
Sarcoidosis (restrictive pattern): Granulomatous infiltration causing diastolic dysfunction, conduction system disease, and ventricular arrhythmias; immunosuppression (corticosteroids) may improve cardiac function if caught early^[18]
Hemochromatosis: Iron deposition in the myocardium — hereditary (HFE gene) or secondary to chronic transfusions; restrictive then dilated phenotype; phlebotomy or chelation may be partially reversible if diagnosed early
Fabry disease: X-linked lysosomal storage disorder (GLA gene, alpha-galactosidase A deficiency); mimics HCM on echo; enzyme replacement therapy (agalsidase beta) or oral chaperone (migalastat) can slow progression; suspect in unexplained LVH especially with renal dysfunction, corneal verticillata, or neuropathic pain

❤️ For families: "Why did this happen?"

This is one of the most common and most important questions families ask. The honest answer is that cardiomyopathy is usually caused by factors completely beyond the patient's control — a genetic variant inherited from a parent who may never have been diagnosed, a virus that attacked the heart muscle years ago, or simply the passage of time causing a normal protein to misfold. In a minority of cases, alcohol or a cancer treatment may have contributed, but even these exposures do not affect every person equally — genetic susceptibility determines who develops heart disease and who does not. Your loved one did not cause this. Nothing they did — or failed to do — would have prevented this outcome with certainty. This is the heart muscle failing, and it is not their fault.

⚕ Clinician note: Genetic counseling

Genetic counseling is appropriate even at hospice enrollment — and this is not academic. For DCM patients with known or suspected LMNA mutations, first-degree relatives face a significant risk of sudden cardiac death from arrhythmias, often before overt heart failure develops. Early identification allows prophylactic ICD placement that saves lives. For TTN truncating variants, the clinical implications for family members are less severe but still warrant surveillance echocardiography. For HCM (MYH7, MYBPC3), cascade genetic testing of first-degree relatives is standard of care — affected family members need screening echocardiograms and possibly activity restriction. For ATTR-CM with the Val122Ile variant — present in 3–4% of Black Americans — all first-degree relatives should be offered TTR gene testing and, if positive, cardiac surveillance with echocardiography and Tc-99m PYP scanning. This is a treatable disease with tafamidis, and early diagnosis in relatives changes outcomes. The hospice enrollment is not too late for these conversations — it may be the catalyst that finally makes them happen.^[10]^[20]

S04 Clinician Everyone

Treatments & Procedures

What disease-directed treatments this patient may have received or may still be receiving. Understanding prior therapy helps anticipate complications and interpret the patient's trajectory.

The treatment landscape for end-stage cardiomyopathy is defined by a progression from medical therapy to device therapy to transplant — a cascade that most hospice patients have moved through entirely before enrollment. Unlike cancer, where treatment failure is typically a linear decline through lines of therapy, heart failure treatment failure is a complex interplay of escalating medical optimization, device implantation, and ultimately the decision about advanced surgical therapies. Every patient on your census with end-stage cardiomyopathy has a unique treatment history that determines their current device burden, medication regimen, anticoagulation requirements, and the ethical complexity of their end-of-life care. Understanding what was tried, what failed, and what hardware remains in place is essential for every visit.^[5]

Medical Therapy (GDMT)

Four pillars of GDMT for DCM/HFrEF: (1) ARNI (sacubitril/valsartan — PARADIGM-HF; first-line over ACEi/ARB; reduces mortality 20% vs. enalapril) or ACEi/ARB if ARNI not tolerated; (2) Beta-blocker (carvedilol, metoprolol succinate, or bisoprolol — only these three have mortality benefit); (3) MRA (spironolactone or eplerenone — RALES, EMPHASIS-HF; watch K⁺ and creatinine); (4) SGLT2 inhibitor (dapagliflozin or empagliflozin — DAPA-HF, EMPEROR-Reduced; benefit across EF spectrum)^[5]^[21]
Hydralazine/isosorbide dinitrate: For patients who cannot tolerate ARNI/ACEi/ARB (renal insufficiency, hyperkalemia); A-HeFT demonstrated particular benefit in self-identified Black patients with HFrEF^[22]
Ivabradine: If-channel blocker; for patients in sinus rhythm with HR ≥70 despite maximized beta-blocker; SHIFT trial — reduces HF hospitalization^[23]
Mavacamten (Camzyos): First-in-class cardiac myosin inhibitor for obstructive HCM with LVOT obstruction; EXPLORER-HCM — reduces LVOT gradient, improves symptoms and exercise capacity; requires REMS program with serial echo monitoring for EF; does not apply to end-stage burned-out HCM^[24]
Tafamidis (Vyndamax/Vyndaqel) 61 mg daily: TTR stabilizer for ATTR cardiac amyloidosis; ATTR-ACT trial — 30% reduction in all-cause mortality, 32% reduction in cardiovascular hospitalizations at 30 months; well-tolerated with no significant drug interactions; should be continued in hospice — one of the clearest examples of targeted therapy continuation at end of life^[4]
Patisiran (Onpattro): RNA interference therapy for hereditary ATTR — reduces hepatic TTR production by ~80%; APOLLO trial showed improvement in neuropathy; APOLLO-B showed cardiac benefit; IV infusion every 3 weeks; increasingly used for ATTRv with cardiac involvement^[25]

Device Therapy

Implantable cardioverter-defibrillator (ICD): Primary prevention in DCM with EF ≤35% despite ≥3 months GDMT (SCD-HeFT); secondary prevention after survived cardiac arrest or sustained VT; does not improve heart failure symptoms — only prevents arrhythmic death; deactivation is a core hospice conversation^[13]
Cardiac resynchronization therapy (CRT/CRT-D): Biventricular pacing for EF ≤35% + LBBB + QRS ≥150 ms; MADIT-CRT, COMPANION trials; improves EF by ~10%, reduces HF hospitalizations, improves symptoms; ~30% of patients are "non-responders"; CRT-D combines CRT with ICD function^[26]
LVAD — see dedicated card below: Left ventricular assist device; continuous-flow centrifugal pump (HeartMate 3) that augments or replaces native LV function; requires surgical implantation, continuous anticoagulation, and daily device management

LVAD Specifics — The Technology That Defines Hospice Care in This Population

HeartMate 3 (Abbott): Current standard — fully magnetically levitated centrifugal-flow pump; reduced pump thrombosis vs. prior devices (MOMENTUM 3 trial); intrinsic artificial pulse feature reduces GI bleeding; most common device you will encounter in new LVAD patients^[27]
HeartMate II (Abbott): Axial-flow pump; still encountered in long-term survivors — some patients have been on HeartMate II for 10+ years; higher rates of pump thrombosis and GI bleeding than HeartMate 3; no longer implanted but remains in the field
HeartWare HVAD (Medtronic): Centrifugal-flow pump; discontinued June 2021 due to increased risk of neurologic adverse events (stroke) and device malfunction (restart failures); patients with existing HVADs require heightened surveillance; some have been explanted and replaced with HeartMate 3; if you encounter an HVAD patient, confirm with the implanting center whether an exchange has been discussed^[28]
Indications: BTT (bridge to transplant — LVAD maintains patient until a donor heart is available), DT (destination therapy — LVAD is the final therapy, no transplant planned; now the majority of implants), BTC (bridge to candidacy — LVAD implanted to improve end-organ function and re-establish transplant eligibility), bridge to recovery (rare — myocardial recovery allows LVAD explant, most described in peripartum CMP and myocarditis)^[2]
Complications: Stroke (ischemic or hemorrhagic — most feared complication; annual rate 8–12% in older devices, reduced with HeartMate 3), GI bleeding from acquired von Willebrand syndrome and arteriovenous malformations (AVMs — continuous flow destroys large vWF multimers), driveline infection (most common infectious complication — percutaneous driveline is a permanent break in skin integrity), pump thrombosis (requires pump exchange or urgent transplant if DT), right heart failure (the LVAD unloads the LV, increasing RV preload — up to 20–30% develop significant RV failure post-implant)^[14]
Daily management in hospice: Driveline exit site sterile dressing changes (per implanting center protocol — typically every 48 hours; aseptic technique critical), controller monitoring (alarms for low flow, high power, low battery — families are trained to respond; hospice team must learn the alarm meanings), battery management (two batteries lasting ~10–14 hours total; must be charged and rotated; backup batteries essential), INR monitoring (warfarin anticoagulation — target typically 2.0–3.0; some centers add aspirin; home INR testing with CoaguChek devices), power source management (wall power overnight, battery power during day; power outages require emergency generator or battery backup plan)^[2]

Surgical Therapies

Heart transplant: The only cure for end-stage cardiomyopathy — ~3,500 performed annually in the US through the UNOS allocation system; donor supply is the rate-limiting factor; average wait time 2–3 years (varies by blood type, body size, sensitization, geography); 1-year survival ~90%, median survival ~12–14 years; requires lifelong immunosuppression (tacrolimus, mycophenolate, prednisone) with risks of rejection, infection, malignancy, and cardiac allograft vasculopathy^[3]
Septal myectomy (Morrow procedure): Open-heart surgical resection of hypertrophied septum for obstructive HCM with LVOT gradient ≥50 mmHg refractory to medical therapy; gold standard with <1% mortality at experienced centers; alternative to alcohol septal ablation; not applicable to end-stage burned-out HCM^[19]
Transplant delisting — causes to document: New malignancy (excludes transplant candidacy), irreversible renal failure (combined heart-kidney transplant may be considered), BMI outside acceptable range, active substance use, progressive frailty despite LVAD support, fixed pulmonary hypertension (PVR >5 Wood units unresponsive to vasodilators), non-adherence, patient decision to withdraw from the list. Delisting carries a unique grief — the loss of a concrete hope — that the hospice team must address directly.^[3]

Comfort-Directed Therapies in Hospice

Comfort inotrope infusion: Continuous dobutamine (2.5–5 mcg/kg/min) or milrinone (0.125–0.375 mcg/kg/min) via PICC or tunneled central line; no survival benefit but reduces congestion, improves cardiac output, and relieves dyspnea and fatigue; allows patient to interact with family; can be managed in home hospice setting with pump and nursing visits^[29]
Aggressive diuresis: IV furosemide (bolus or continuous infusion), metolazone (synergistic with loop diuretics for diuretic resistance), spironolactone/eplerenone for neurohormonal benefit and potassium sparing; goal is decongestion for symptom relief — reduction in dyspnea, orthopnea, edema, and ascites^[5]
Paracentesis and thoracentesis: For refractory ascites or pleural effusions causing dyspnea; can be performed in the home by trained hospice clinicians; often provides dramatic symptom relief
Opioids for dyspnea: Low-dose morphine (2–5 mg PO/SL q4h or CSCI 10–20 mg/24h) reduces the sensation of breathlessness without clinically significant respiratory depression at these doses; first-line for refractory dyspnea in end-stage heart failure^[30]

S05 Clinician

When Therapy Makes Sense

Evidence-based criteria for continuing disease-directed therapy. This is not about giving up or holding on — it's about reading the data correctly.

End-stage cardiomyopathy on hospice does not mean all disease-directed therapy stops. Unlike many malignancies, several cardiomyopathy-specific therapies demonstrably improve both symptoms and survival even in the final months of life. The key clinical judgment is distinguishing therapies that meaningfully improve the patient's lived experience from those that impose burden without benefit. The 2022 AHA/ACC/HFSA heart failure guidelines and the 2023 ISHLT guidelines for mechanical circulatory support both support continued disease-specific therapy when it aligns with patient goals and functional status.^[5]^[6]

01

Tafamidis 61 mg daily for confirmed ATTR-CM with ECOG 0–2. The ATTR-ACT trial demonstrated a 30% reduction in all-cause mortality and 32% reduction in cardiovascular-related hospitalizations over 30 months. Tafamidis is well-tolerated, has no significant drug interactions, and is taken as a single daily oral capsule. This is arguably the clearest example of a disease-directed therapy that should continue through hospice enrollment. Stopping it as reflexive deprescribing is a clinical error — the drug is providing ongoing mortality benefit with near-zero side effect burden.^[4]
02

Mavacamten for obstructive HCM with LVOT obstruction in ECOG 0–2. EXPLORER-HCM demonstrated significant reduction in LVOT gradient and improvement in functional capacity and symptoms. If the patient is on mavacamten with good response and is enrolled in hospice for a comorbid condition or for general trajectory management rather than acute HCM crisis, continuation is appropriate. Requires REMS echo monitoring — coordinate with cardiology. Does not apply to burned-out HCM.^[24]
03

LVAD optimization if enrolled for support needs, not LVAD failure. Some patients enroll in hospice because they need the complex care management that hospice provides — driveline care, symptom management, family support — not because the LVAD has failed. In these cases, LVAD speed optimization, anticoagulation management, and routine device monitoring should continue. The LVAD is a comfort device for these patients. Hospice teams must partner with the LVAD coordinator at the implanting center.^[2]
04

Comfort inotrope infusion (dobutamine or milrinone) for refractory Stage D without LVAD. Continuous low-dose inotrope infusion provides meaningful relief from congestion, dyspnea, and fatigue in patients with refractory Stage D heart failure who are not LVAD candidates. No survival benefit, but dramatic quality-of-life improvement in well-selected patients. Can be managed in the home setting with a PICC line and ambulatory infusion pump. This is palliative therapy at its most effective.^[29]
05

ICD deactivation for patients who have chosen comfort goals. When a patient has explicitly chosen comfort-focused care and does not want resuscitation, the ICD's shock function should be deactivated. ICD shocks in the final days of life are painful, distressing, and provide no meaningful clinical benefit when the underlying heart failure is terminal. Anti-tachycardia pacing (ATP) may be left active — it is painless and may terminate VT without the trauma of a shock. Deactivation requires a magnet or device interrogation by an industry representative or electrophysiology team.^[13]
06

LVAD continuation as comfort modality when patient chooses this with full understanding. Many patients and families choose to continue the LVAD through the dying process — and this is a valid, supported decision. The LVAD may be providing enough cardiac output to allow the patient to be alert, conversational, and present with family. The hospice team's role is to ensure this is a fully informed choice (the patient understands what deactivation means and has chosen not to pursue it now), to continue LVAD maintenance, and to plan for eventual device failure or the patient's later decision to deactivate.^[6]
07

Palliative diuresis optimization (IV furosemide, metolazone, MRA). Congestion — fluid overload causing dyspnea, edema, ascites, and hepatic congestion — is the dominant source of suffering in end-stage cardiomyopathy. Aggressive diuresis is a comfort intervention. IV furosemide (bolus or continuous infusion at home via ambulatory pump), oral metolazone 2.5–5 mg 30 minutes before loop diuretic for synergistic effect, and MRA continuation all serve the hospice goal of reducing suffering. Monitor electrolytes and renal function, but prioritize symptom relief over lab values at this stage.^[5]

S06 Clinician

When It Doesn't

Knowing when treatment stops helping is not clinical failure. It is the most important clinical skill in this disease.

Heart failure is the most under-referred diagnosis in hospice care. Patients with end-stage cardiomyopathy have a median hospice length of stay of fewer than 3 weeks — compared to 2–3 months for many cancers. The reasons are structural: the unpredictable sawtooth trajectory makes prognosis difficult, cardiologists are trained to escalate rather than transition, and the presence of an LVAD creates an illusion of stability that delays the comfort conversation. But the data are clear — patients with ACC/AHA Stage D heart failure who are not LVAD or transplant candidates have a 1-year mortality exceeding 50%, and for those who are inotrope-dependent, median survival without advanced therapies is 3–6 months. The following scenarios represent clear inflection points where disease-directed therapy has reached its limit and hospice enrollment is not just appropriate — it is the highest-quality care available.^[7]^[5]

01

LVAD DT patient with recurrent strokes, device malfunction, or intolerable anticoagulation. When the LVAD — intended as destination therapy — is causing more harm than benefit, the calculus has shifted. Recurrent embolic or hemorrhagic strokes cause cumulative neurologic devastation. Device malfunction (alarms, suction events, power failures) creates constant crisis. Intractable GI bleeding from acquired von Willebrand syndrome may require holding anticoagulation, which then increases stroke risk — an unresolvable therapeutic dilemma. The LVAD has transitioned from life-sustaining to suffering-sustaining. Deactivation conversation is appropriate.^[14]
02

Post-transplant patient with allograft failure, not a re-transplant candidate. Cardiac allograft failure — whether from acute rejection, chronic allograft vasculopathy, or antibody-mediated rejection — in a patient who is not eligible for re-transplantation represents an irreversible terminal trajectory. These patients have already undergone the ultimate therapy. Continuing immunosuppression may be appropriate for comfort (avoiding the acute inflammatory misery of rejection), but escalation of immunosuppressive regimens, mechanical support for a failing allograft, or re-listing when criteria are not met only prolongs suffering.^[3]
03

Delisted transplant candidate declining LVAD or at end-stage on LVAD. The patient was on the transplant list. They were delisted — because of a new malignancy, progressive renal failure, frailty, fixed pulmonary hypertension, or their own choice. If they decline LVAD implantation (or already have an LVAD that is no longer providing adequate support), they have exhausted all options for disease modification. This is the clearest hospice-appropriate scenario. The unique grief of delisting — the loss of the "transplant hope" — must be addressed directly by the team.^[6]
04

ECOG ≥3 with DCM/HCM/ATTR-CM despite optimal therapy. A patient confined to bed or chair for more than 50% of waking hours despite maximized GDMT, optimized device therapy, and adequate volume management has reached a functional threshold where disease-directed therapy offers diminishing returns. At ECOG 4 (completely bedbound), the focus must shift entirely to comfort. GDMT medications may be contributing to hypotension and fatigue at this point — judicious deprescribing of beta-blockers and vasodilators can paradoxically improve quality of life by reducing symptomatic hypotension.^[5]
05

Refractory VT storm — recurrent ICD shocks or incessant VT despite antiarrhythmic therapy and ablation. Ventricular tachycardia storm (≥3 sustained VT episodes or ICD shocks in 24 hours) that persists despite IV amiodarone, lidocaine, deep sedation, and catheter ablation represents an arrhythmic crisis that is unlikely to resolve. Each ICD shock is excruciatingly painful and psychologically devastating — for the patient and for the family witnessing it. If the underlying cardiomyopathy substrate is not amenable to further ablation and the VT is incessant, ICD deactivation with palliative sedation is the compassionate path. Continuing to shock a dying patient is not treatment — it is harm.^[13]
06

New malignancy or organ failure removing transplant candidacy — the delisting grief scenario. A patient on the transplant list who develops a new cancer, progressive renal failure requiring dialysis, severe hepatic dysfunction, or irreversible neurologic injury will be delisted. This is a singular grief event. The patient had a timeline, a hope, a pager that might ring with a donor heart. That is now gone. The hospice team must name this grief specifically — not with euphemisms about "God's plan" or "everything happens for a reason," but with direct acknowledgment: "You lost something real. The transplant was a real hope, and it was taken away. We are here to walk with you through what comes next."^[3]
07

Patient goals shift explicitly to comfort, home, and presence. When a fully informed patient — who understands their prognosis, the options that remain, and the burdens of continuing — says "I want to be home, I want to be comfortable, I want to be with my family" — that is not giving up. That is the clearest possible clinical directive. Honor it without delay, without a "but have you considered…" qualifier, and without waiting for the cardiologist to agree. The patient's articulated goals are the treatment plan. Build everything around them.

⚠️ LVAD Deactivation — This Is Different

LVAD deactivation causes death from cardiogenic shock within minutes to hours. This is fundamentally different from ICD deactivation, which merely removes the safety net against arrhythmic death but does not directly cause it. LVAD deactivation is ethically and legally equivalent to withdrawing mechanical ventilation — it is the removal of a life-sustaining therapy, not the withdrawal of a preventive device. The AHA, ACC, ISHLT, and HFSA all affirm this ethical equivalence in published position statements.^[6]

LVAD deactivation requires palliative sedation planning before the event. The patient will experience progressive cardiogenic shock — hypotension, air hunger, agitation, and distress. Pre-medication with midazolam 5–10 mg SQ/IV and morphine 5–10 mg SQ/IV is mandatory. Additional doses must be drawn up and at bedside before deactivation begins. The LVAD coordinator from the implanting center should be present (in person or by phone) to guide the technical deactivation. Chaplaincy should be offered. The family must be prepared for what they will witness — the alarms, the silence after the pump stops, the timeline of the dying process. This is not a bedside procedure — it is a planned, sacred, clinical event that requires the same level of preparation as any other withdrawal of life support.^[31]

S07 Everyone

Out-of-the-Box Approaches

Evidence-graded integrative, interventional, and complementary approaches. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.

LVAD Deactivation as Planned Comfortable Death

Grade A

AHA/ACC/ISHLT/HFSA guidelines confirm that LVAD deactivation is ethically equivalent to withdrawing any life-sustaining therapy — including mechanical ventilation, dialysis, or artificial nutrition. It is supported by every major cardiology and palliative care professional society and is legal in all 50 US states.^[6]^[31]

Protocol: Palliative sedation with midazolam 5–10 mg SQ/IV + morphine 5–10 mg SQ/IV administered 15–30 minutes before deactivation. Additional rescue doses drawn up at bedside (midazolam 5 mg, morphine 5 mg — repeat PRN q10 min for distress). Glycopyrrolate 0.2–0.4 mg SQ available for secretion management. Family prepared and present. LVAD coordinator present or on phone for technical guidance. Chaplain present or offered. The pump is turned off by reducing speed to zero or disconnecting the controller. Death follows from progressive cardiogenic shock — typically within minutes to hours depending on degree of native cardiac function. The setting must be quiet, private, and unhurried. This is a planned death and should carry the gravity of that designation.

Key point: Some LVAD patients retain enough native cardiac function to survive hours or even days after deactivation. The team must prepare the family for this possibility — it does not mean the decision was wrong or that the patient is "fighting." It means the native heart is providing some residual output. Continue comfort medications and reassess sedation needs throughout.

Tafamidis Continuation in ATTR-CM Hospice Patients

Grade A

The ATTR-ACT trial (Maurer et al., NEJM 2018) randomized 441 patients with ATTR cardiac amyloidosis to tafamidis 80 mg or 20 mg vs. placebo. At 30 months, tafamidis reduced all-cause mortality by 30% (HR 0.70; 95% CI 0.51–0.96) and cardiovascular-related hospitalizations by 32%. The benefit was consistent across wild-type and hereditary ATTR subtypes.^[4]

Dose: Tafamidis 61 mg (Vyndamax) once daily — this is a single capsule, well-tolerated, with no clinically significant drug interactions with opioids, diuretics, anticoagulants, or any common hospice medication.

Hospice implication: Tafamidis is one of the clearest examples of targeted therapy continuation in hospice. It reduces hospitalizations (reducing patient suffering and family disruption), reduces mortality (extending time with family), and imposes essentially zero side effect burden. Stopping tafamidis as reflexive deprescribing at hospice enrollment is a clinical error. The drug should continue until the patient can no longer swallow or until death is imminent (hours to days). Cost may be a barrier — engage pharmacy and social work to explore manufacturer assistance programs.

Palliative Inotrope Infusion in End-Stage CMP

Grade B

Continuous subcutaneous or IV infusion of dobutamine or milrinone for refractory Stage D heart failure without LVAD. Multiple observational studies and registry analyses demonstrate significant improvement in heart failure symptoms, functional capacity, and patient-reported quality of life, despite no survival benefit and a possible increase in arrhythmic events.^[29]

Dobutamine: 2.5–5 mcg/kg/min via PICC or tunneled central line; ambulatory infusion pump; positive inotrope and mild vasodilator; may cause tachycardia and arrhythmias at higher doses.

Milrinone: 0.125–0.375 mcg/kg/min via PICC or tunneled central line; phosphodiesterase-3 inhibitor with inotropic and vasodilator effects; may cause more hypotension than dobutamine; preferred in patients on beta-blockers (mechanism is independent of beta-receptor pathway).

Hospice context: This is not futile care — it is one of the most effective palliative interventions available for end-stage heart failure. A patient who has been bedbound, dyspneic, and unable to interact with family may, within 24–48 hours of inotrope initiation, be sitting up, eating, talking, and engaged. The value is measured not in survival weeks but in quality hours. Requires home nursing support for line management and infusion pump monitoring.

Comfort-Focused LVAD Optimization

Grade B

For hospice patients who choose to continue the LVAD, the device can be managed with a comfort-first rather than longevity-first approach. This involves collaboration between the hospice team and the LVAD coordinator at the implanting center.^[2]

Speed adjustments: LVAD speed can be optimized for symptom relief rather than hemodynamic targets. Lower speeds may reduce suction events and allow more pulsatility; higher speeds may better unload a congested LV. The goal shifts from "optimize CI" to "reduce dyspnea and edema."

Anticoagulation modification: In patients with recurrent GI bleeding, reducing or discontinuing anticoagulation — accepting increased thrombotic risk — may be appropriate if bleeding is causing more suffering than the theoretical stroke risk. This risk-benefit calculus changes fundamentally in the comfort-focused setting.

Fluid management: Diuretic adjustments in coordination with LVAD parameters — flow and PI trends can guide volume status assessment when physical exam is difficult. The LVAD team can provide remote parameter review in many cases.

Key point: Comfort-focused LVAD management is not substandard care. It is a deliberate, goal-concordant reorientation of device management from survival optimization to suffering minimization. Document the rationale clearly.

Cardiac Rehabilitation Adaptation for Hospice

Grade C

Modified gentle exercise programs for LVAD patients on hospice with ECOG 1–2. Limited clinical data in the hospice-specific population, but cardiac rehabilitation in ambulatory LVAD patients has demonstrated improvements in functional capacity (6-minute walk distance), quality of life, and depression scores in multiple single-center studies and one multicenter trial (REHAB-VAD).^[32]

Approach: Supervised gentle ambulation (hallway walks, seated exercises), range-of-motion work, breathing exercises. Physical therapy consult through hospice benefit. Sessions tailored to daily functional capacity — no fixed targets, no progression expectations. Goal is maintenance of function and autonomy, not cardiopulmonary conditioning.

Safety considerations: LVAD patients have altered hemodynamic responses to exercise — blood pressure measurement by Doppler only (no palpable pulse with continuous-flow devices). Avoid Valsalva maneuvers. Monitor controller parameters before and after activity. Stop for any alarm or symptom change. Fall risk is elevated due to driveline tethering and orthostatic intolerance.

Hospice context: The ability to walk to the kitchen, sit in a chair on the porch, or stand for a shower has profound meaning for a patient who has been hospitalized repeatedly. This is not "exercise" in the traditional sense — it is preservation of personhood and dignity.

Palliative Sedation Protocol for LVAD Deactivation

Grade A — Guideline

A structured pre-deactivation sedation protocol is mandatory for any planned LVAD deactivation. This is supported by AHA/HFSA position statements, ISHLT guidelines, and expert consensus from multiple palliative care and mechanical circulatory support centers.^[6]^[31]

Pre-deactivation medications (administer 15–30 minutes before):

Midazolam 5–10 mg SQ or IV — for anxiolysis and sedation
Morphine 5–10 mg SQ or IV — for dyspnea and pain prophylaxis
Glycopyrrolate 0.2–0.4 mg SQ — for anticipated secretions (optional, administer if secretion burden expected)
Haloperidol 1–2 mg SQ — for anticipated terminal restlessness (optional, have available)

At bedside before deactivation begins:

Midazolam 5 mg SQ/IV — rescue dose, repeat q10 min PRN for agitation or distress
Morphine 5 mg SQ/IV — rescue dose, repeat q10 min PRN for dyspnea
Lorazepam 2 mg SL — alternative anxiolytic if IV/SQ access fails
Suction equipment available but rarely needed

Process: Confirm patient is comfortable and adequately sedated before proceeding. LVAD coordinator reduces pump speed to off or disconnects controller per device-specific protocol. Monitor patient for signs of distress — administer rescue medications immediately if any distress is observed. Do not wait. Continue monitoring and medicating until death. Time from deactivation to death varies from minutes to hours depending on native cardiac function — prepare the family for both scenarios.

Environment: Private room. Unhurried. Music if patient/family desires. Chaplain present or offered. Family given permission to hold the patient, lie beside them, speak to them. The hospice team's role is to ensure that the patient experiences no suffering and that the family witnesses a peaceful death. There is no clinical event in hospice that demands more preparation, more presence, and more skill than this one.

S08 Everyone

Natural & Herbal Options

Supplements and herbal products in end-stage cardiomyopathy — with critical LVAD anticoagulation safety context that makes this population uniquely dangerous for unvetted supplements.

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"Let me be direct: LVAD anticoagulation makes supplement safety uniquely complex — and uniquely dangerous. Warfarin has an extremely narrow therapeutic window. An INR below 2.0 in an LVAD patient risks pump thrombosis and embolic stroke. An INR above 3.0 risks hemorrhagic stroke and catastrophic GI bleeding from the acquired von Willebrand syndrome these patients already carry. Any supplement that touches CYP2C9 metabolism, vitamin K pathways, or platelet function can tip that balance in either direction — and the result can be fatal within hours. The default answer for any LVAD patient asking about supplements is always the same: check with your LVAD coordinator first. Not your hospice nurse, not the internet, not the health food store — the LVAD coordinator. For non-LVAD cardiomyopathy patients on amiodarone or digoxin, the interaction landscape is equally treacherous — amiodarone inhibits CYP enzymes and doubles warfarin's effect on its own, and digoxin has a vanishingly narrow therapeutic index that hawthorn and St. John's Wort can shatter. I've seen a well-meaning daughter bring in a bag of supplements from the vitamin shop and nearly kill her father. The conversation about supplements in this population is not optional — it is a safety screening."

— Waldo, NP · Terminal2

Herb / Supplement	Evidence Grade	Typical Dose	Potential Benefit	Interactions / Contraindications
Coenzyme Q10 (Ubiquinol)	Grade B	100–200 mg daily	Mitochondrial electron transport chain cofactor essential for myocardial ATP production. The Q-SYMBIO trial demonstrated modest improvement in ejection fraction and reduction in major adverse cardiac events in dilated cardiomyopathy patients supplemented with CoQ10 over 2 years.^[33]	⚠ WARNING: CoQ10 has vitamin K-like structural activity and can reduce INR in patients on warfarin. In LVAD patients, any INR reduction risks pump thrombosis and stroke. Monitor INR closely if used; requires weekly INR checks during initiation. May be more appropriate in non-LVAD cardiomyopathy patients not on warfarin. Do not start without LVAD coordinator approval.
Magnesium Glycinate	Grade C	200–400 mg daily	Magnesium depletion is extremely common in heart failure patients on chronic loop diuretics (furosemide, torsemide). Low serum magnesium increases the risk of atrial and ventricular arrhythmias, potentiates digoxin toxicity, and worsens muscle cramping and fatigue. Repletion may reduce ectopy and improve quality of life.^[34]	Check serum magnesium level before supplementing — both deficiency and excess are problematic. Avoid supplementation if GFR <30 mL/min (impaired renal magnesium excretion risks hypermagnesemia). Glycinate form preferred for GI tolerability over oxide or citrate. May cause loose stools at higher doses.
Omega-3 Fatty Acids (low dose)	Grade C	1 g/day maximum	GISSI-HF trial showed a modest but significant reduction in mortality and hospitalizations in heart failure patients taking 1 g/day of omega-3 polyunsaturated fatty acids. Modest anti-inflammatory and anti-arrhythmic signal. AHA guidelines support low-dose omega-3 in HFrEF.^[35]	⚠ LVAD CAUTION: Above 1 g/day, omega-3 fatty acids have a significant antiplatelet effect that compounds bleeding risk in LVAD patients already on aspirin + warfarin. At 1 g/day, the antiplatelet effect is minimal and generally considered safe. Do not exceed 1 g/day in any anticoagulated patient. Monitor for increased bruising or GI bleeding.
Melatonin	Grade C	1–3 mg QHS	Sleep disruption is pervasive in LVAD patients — caused by controller alarms, anxiety about device function, nocturnal Cheyne-Stokes respiration, and the psychological burden of living on a machine. Melatonin supports circadian rhythm entrainment and sleep onset without the hemodynamic effects of sedative-hypnotics.^[36]	Minimal cardiac drug interactions — one of the safest supplements in the cardiomyopathy population. No effect on INR, no CYP interference at standard doses, no hemodynamic effects. May cause morning grogginess at doses above 3 mg. Avoid extended-release formulations if hepatic congestion is present. Can be used concurrently with lorazepam if needed.
L-Carnitine	Grade C	1–2 g daily, divided doses	Mitochondrial fatty acid transport cofactor supporting myocardial energy metabolism. Some evidence of benefit in dilated cardiomyopathy — a meta-analysis suggested improvement in ejection fraction and exercise capacity, though individual trials are small and results are mixed.^[37]	Well-tolerated at standard doses. GI side effects (nausea, diarrhea) are the most common complaints. No significant interactions with warfarin, amiodarone, or digoxin. Evidence is insufficient to recommend routinely, but risk is low. May cause a fishy body odor at higher doses. Use acetyl-L-carnitine form if cognitive benefit is also desired.
Thiamine (Vitamin B1)	Grade B	100–200 mg daily	Thiamine deficiency is common in heart failure patients on chronic loop diuretics — furosemide increases renal thiamine excretion. Deficiency impairs myocardial energy production and can worsen cardiac function. Multiple studies demonstrate that thiamine supplementation may improve ejection fraction by 3–6% in deficient HF patients.^[38]	Safe. No significant drug interactions with any cardiac medication. No effect on INR or anticoagulation. Water-soluble vitamin — excess is renally excreted. Check thiamine level (erythrocyte transketolase or whole blood thiamine) if deficiency is suspected, but empiric supplementation is reasonable given the safety profile and high prevalence of deficiency in this population.
Hawthorn Berry Extract	Grade C	450–900 mg daily, divided doses	The WS 1442 standardized hawthorn extract was studied in the SPICE trial (2,681 patients with NYHA II–III heart failure). The primary endpoint was not met, but there was a modest signal for symptomatic benefit and a trend toward reduced sudden cardiac death in the subgroup with EF 25–35%. Mechanism involves increased coronary flow and positive inotropic effects.^[39]	⚠ MAY POTENTIATE CARDIAC GLYCOSIDES: Hawthorn contains flavonoids and oligomeric procyanidins with positive inotropic properties that may compound with digoxin — risk of digoxin toxicity. Avoid in patients on digoxin. Avoid combining with antiarrhythmics (amiodarone, sotalol) due to additive QT effects. Mild vasodilatory effect — may potentiate hypotension from ACEi/ARB/ARNI. Not recommended in LVAD patients without cardiology guidance.

⛔ Supplements to Avoid in End-Stage Cardiomyopathy

St. John's Wort (Hypericum perforatum) — Potent inducer of CYP3A4 and P-glycoprotein. Reduces warfarin levels dangerously in LVAD patients — can drop INR below therapeutic range within days, risking pump thrombosis and embolic stroke. Also significantly reduces amiodarone levels (CYP3A4 substrate) and digoxin levels (P-glycoprotein substrate). Contraindicated in any patient on warfarin, amiodarone, or digoxin.^[40]
Ginkgo Biloba — Antiplatelet effect through inhibition of platelet-activating factor (PAF). Adds directly to the bleeding risk of aspirin + warfarin regimens. Especially dangerous in LVAD patients who already carry acquired von Willebrand syndrome and elevated GI bleeding risk. Multiple case reports of serious bleeding events in anticoagulated patients taking ginkgo.^[40]
Ginseng (Panax ginseng) — May reduce warfarin efficacy and lower INR through unclear mechanisms — possibly CYP induction or vitamin K-like effects. Potential for hemodynamic effects including blood pressure changes. Inconsistent pharmacokinetic data makes safe coadministration with warfarin unpredictable. Avoid in all anticoagulated cardiomyopathy patients.^[40]
Vitamin E (high-dose >400 IU) — High-dose vitamin E has antiplatelet effects that compound bleeding risk in patients on aspirin and/or warfarin. The HOPE-TOO trial also raised concerns about increased heart failure hospitalizations with high-dose vitamin E (400 IU/day). Avoid doses above 400 IU in any anticoagulated patient. Low-dose dietary vitamin E is not a concern.^[41]
Garlic Supplements (concentrated/aged extracts) — Concentrated garlic supplements have antiplatelet activity (inhibits thromboxane synthesis) and CYP2C9 effects that can potentiate warfarin. The antiplatelet effect is additive with aspirin. Fresh dietary garlic in normal cooking amounts is unlikely to cause clinical problems, but concentrated supplement forms are dangerous in LVAD patients on warfarin + aspirin.^[40]
Dong Quai (Angelica sinensis) / Danshen (Salvia miltiorrhiza) — Both dramatically potentiate warfarin's anticoagulant effect. Dong quai contains coumarins that add to warfarin's mechanism. Danshen inhibits warfarin metabolism and has intrinsic anticoagulant properties. Both have caused life-threatening bleeding events when combined with warfarin. Absolutely contraindicated in any patient on LVAD anticoagulation. Alert families who use traditional Chinese medicine — these are common components of herbal formulations.^[42]

S09 Everyone

Timeline Guide

The trajectory of end-stage cardiomyopathy from advanced disease through death — with distinct pathways for LVAD patients, non-LVAD patients, and ATTR-CM.

End-stage cardiomyopathy follows three distinct trajectories depending on subtype and device status, and understanding which trajectory your patient is on determines every clinical decision. DCM with LVAD follows a technology-dependent course — the patient may be clinically stable for months to years on the device, with the trajectory defined not by gradual cardiac decline but by the accumulation of device complications (stroke, GI bleeding, driveline infection, right heart failure) until either the complications become unmanageable or the patient chooses deactivation. HCM at end-stage follows the "burned-out" pathway — years of compensated hypertrophy give way to progressive dilation and systolic failure, often with refractory arrhythmias, and the decline can be surprisingly rapid once the ventricle begins to thin. ATTR-CM on tafamidis follows the slowest trajectory — tafamidis slows but does not halt disease progression, and patients may have months to years of gradual functional decline with progressive diastolic failure, conduction disease, and autonomic dysfunction. All three trajectories share the characteristic heart failure sawtooth pattern — acute exacerbations followed by partial recovery — that makes prognostication notoriously difficult and hospice referral chronically late.^[7]^[5]

YRS–MOS

Phase 1 — Early Advanced / Device Integration

The patient has ACC/AHA Stage C or early Stage D heart failure with cardiomyopathy. Guideline-directed medical therapy (GDMT) is maximized or near-maximum. An ICD is in place for primary or secondary prevention of sudden cardiac death. The transplant evaluation may be underway or complete — the patient may be on the UNOS waitlist, or candidacy discussions are active. For DCM patients, LVAD implantation has occurred or is being planned — as bridge to transplant (BTT) if the patient is listed, or as destination therapy (DT) if transplant is not an option. The early post-LVAD period involves intensive device education for patient and caregiver, driveline site care training, anticoagulation titration, and adjustment to life on a machine. For HCM patients, this phase represents compensated disease on medical therapy (beta-blockers, disopyramide, or mavacamten for obstructive physiology) with the knowledge that a subset will progress to the burned-out phenotype. For ATTR-CM patients, tafamidis has been initiated and the disease is progressing slowly — often over years — with gradual decline in exercise tolerance and increasing diuretic requirements.^[5]^[2]

Palliative care integration is valuable here — particularly for LVAD patients navigating device decisions, transplant candidacy uncertainty, and the psychological burden of living on mechanical support. Early palliative involvement improves symptom management, reduces depression, and facilitates advance care planning conversations that become exponentially harder to initiate later.^[6]

MOS–1YR

Phase 2 — Complication Accumulation / Candidacy Loss

This is the phase where the trajectory begins to declare itself. For LVAD patients, device-related complications are emerging and accumulating: GI bleeding episodes from acquired von Willebrand syndrome requiring transfusions and anticoagulation adjustments; driveline exit site infection (erythema progressing to purulent drainage, positive cultures, need for suppressive antibiotics); embolic or hemorrhagic stroke causing new neurologic deficits; right heart failure worsening despite LVAD-mediated left ventricular unloading, manifesting as hepatic congestion, ascites, and renal dysfunction. Each complication reduces functional status, increases caregiver burden, and narrows the remaining clinical options.^[14]

For patients previously on the transplant waitlist, delisting is occurring — triggered by a new comorbidity (malignancy, irreversible renal failure, fixed pulmonary hypertension), progressive frailty, or the patient's own decision. Delisting is a singular grief event that the team must name and address. For HCM patients, the transition to the burned-out phase is becoming apparent — the septum is thinning on serial echocardiography, the EF is dropping below 50%, and the clinical picture is shifting from diastolic dysfunction to combined systolic-diastolic failure. For ATTR-CM patients, disease is advancing toward Mayo Stage III — NT-proBNP and troponin are rising, functional class is worsening, and conduction disease may require permanent pacing.^[3]^[12]

This is the critical palliative integration window. Hospice referral conversations should be happening now — not at the next crisis. The median hospice length of stay for heart failure is under 3 weeks, which means most patients are referred far too late to benefit fully from what hospice can offer.^[7]

WKS–MOS

Phase 3 — Hospice Transition / LVAD as Destination Only

Heart transplant is no longer an option — the patient has been delisted, has declined transplant, or was never a candidate. The LVAD, if present, is now definitively destination therapy. Complications continue to accumulate: recurrent GI bleeding requiring dose-reduction or cessation of anticoagulation (accepting increased thrombotic risk), progressive driveline infection that may be tracking deeper despite suppressive antibiotics, worsening right heart failure with refractory edema and ascites, declining renal function limiting diuretic efficacy. For non-LVAD patients, this is refractory Stage D heart failure — inotrope-dependent, diuretic-resistant, functionally bedbound for increasing portions of the day.^[5]

The LVAD deactivation discussion should begin in this phase. Not as a recommendation, but as an exploration: "As things get harder, I want to make sure we've talked about all your options — including what you want to happen with the device." The goal is to ensure the patient has the information they need to make an autonomous decision when the time comes, not to pressure them toward a choice they are not ready for. Document the conversation. Revisit it. Allow ambivalence — it is natural and should not be rushed.^[6]^[31]

DAYS–WKS

Phase 4 — Pre-Active / LVAD Deactivation Planning

Functional status has declined to ECOG 3–4. The patient is bedbound or chair-bound for the majority of waking hours. Dyspnea at rest is persistent despite maximum diuretic therapy and, if applicable, comfort inotrope infusion. Anorexia, cachexia, and cognitive cloudiness from poor cardiac output are evident. The LVAD, if still running, may be providing the only meaningful cardiac output — native ventricular function is negligible. For non-LVAD patients, signs of end-organ failure are progressing: rising creatinine, declining urine output, hepatic congestion with rising bilirubin, and lactic acidosis from poor perfusion.^[5]

The LVAD deactivation conversation or request is happening now. The patient or surrogate decision-maker has indicated readiness, or the clinical team has initiated the discussion based on the accumulating burden of device complications. The palliative sedation protocol must be prepared: midazolam and morphine ordered, drawn up, labeled, and confirmed at bedside. The LVAD coordinator from the implanting center has been contacted and the deactivation procedure confirmed. Chaplaincy has been offered. The comfort kit is at the bedside. Family education about what death looks like after LVAD deactivation is essential — they need to know the timeline (minutes to hours), the expected physical changes (progressive hypotension, mottling, altered breathing, decreased consciousness), and that the team will ensure their person feels no pain or distress. For non-LVAD patients, comfort kit preparation and family education about the dying process follow standard end-stage heart failure protocols.^[31]

HRS–DAYS

Phase 5 — Final Hours

For LVAD patients, this is the deactivation event — or natural death from a complication (stroke, sepsis from driveline infection, arrhythmia) while the LVAD is still running. If deactivation is planned, the palliative sedation protocol has been administered: midazolam 5–10 mg SQ/IV and morphine 5–10 mg SQ/IV given 15–30 minutes before. The patient is comfortable and sedated. The LVAD coordinator confirms the device type and talks the team through the deactivation — pump speed reduced to zero or controller disconnected. The pump stops. The alarms sound and are silenced. The family is present. Death follows from progressive cardiogenic shock — the heart, without mechanical support, cannot generate adequate output. Some patients die within minutes; others, with residual native cardiac function, may survive hours. Continue comfort medications throughout. The LVAD coordinator confirms the device is off. The time of death is pronounced.^[31]^[6]

For non-LVAD patients, the final hours follow the trajectory of natural cardiac death: Cheyne-Stokes respiration deepening and becoming more irregular, progressive peripheral mottling beginning at the extremities and advancing centrally, declining blood pressure with weak thready pulse or no palpable pulse, decreasing consciousness, terminal secretions managed with glycopyrrolate, and family at the bedside. Death from cardiogenic shock or terminal arrhythmia. Whether the death follows LVAD deactivation or natural cardiac failure, the standard is the same: the patient experiences no suffering, and the family witnesses a death that is as peaceful as clinical excellence can make it.

S10 Clinician

Medications to Anticipate

Disease-specific medications, LVAD anticoagulation, comfort medications, and the critical LVAD deactivation sedation protocol. Know every drug on this list before your first visit.

LVAD patients require specific pharmacological attention at every visit. Warfarin INR management is not a background task — it is an active, high-stakes clinical responsibility. The INR target for HeartMate 3 devices is 2.0–3.0; sub-therapeutic INR risks pump thrombosis and embolic stroke, while supra-therapeutic INR risks hemorrhagic stroke and catastrophic GI bleeding. Weekly INR monitoring is the standard, and the frequency of monitoring itself becomes a goals-of-care conversation in hospice — how much blood draw burden is the patient willing to tolerate? Driveline infection suppressive antibiotics may be ongoing indefinitely as a comfort measure, not a curative one. And when LVAD deactivation is planned, the complete palliative sedation protocol must be prepared, medications drawn up and labeled, and syringes at bedside BEFORE the deactivation event begins. A patient experiencing cardiogenic shock without adequate pre-sedation is preventable suffering of the highest order.^[2]^[31]

Drug	Class / Target	Starting Dose	Notes
Warfarin	LVAD Anticoagulation	INR target 2.0–3.0 (HeartMate 3)	Weekly INR monitoring is standard for LVAD patients. Home monitoring with CoaguChek devices reduces visit burden. Frequency of monitoring is a GOC conversation in hospice — less frequent monitoring accepts wider INR variation and associated risks. Amiodarone doubles warfarin effect — requires dose reduction. Countless food and drug interactions. LVAD coordinator should remain involved in anticoagulation management through hospice enrollment.^[2]
Aspirin 81 mg	Antiplatelet	81 mg daily	Standard adjunct to warfarin in LVAD patients. Continue unless GI bleeding has become the primary clinical problem — in which case, holding aspirin while continuing warfarin may be appropriate (aspirin contributes more to GI bleeding risk than warfarin in this population). Discuss risk-benefit with LVAD coordinator.^[2]
Furosemide or Torsemide	Loop Diuretic / Fluid Management	Furosemide 40–80 mg PO/IV BID	Ongoing even with LVAD — the device unloads the left ventricle but right heart failure persists and often worsens over time. Congestion (dyspnea, edema, ascites) is the dominant source of suffering in end-stage cardiomyopathy. Aggressive diuresis is a comfort intervention. Torsemide has more predictable oral bioavailability than furosemide. Add metolazone 2.5–5 mg for diuretic resistance. Monitor potassium, magnesium, and creatinine — but prioritize symptom relief over lab values at end of life.^[5]
Spironolactone	MRA / Neurohormonal Modulation	12.5–25 mg daily	Continue if tolerated — neurohormonal benefit (RAAS blockade) and potassium-sparing effect that offsets loop diuretic losses. RALES trial demonstrated 30% mortality reduction in severe HF. Monitor potassium — risk of hyperkalemia increases with declining renal function. Hold if K⁺ >5.5 mEq/L. Consider eplerenone if gynecomastia develops with spironolactone.^[5]
Amiodarone	Antiarrhythmic	200 mg daily (maintenance)	Long half-life (40–55 days) — effects persist for weeks after discontinuation. Doubles warfarin effect through CYP2C9 inhibition — warfarin dose must be reduced ~30–50% when amiodarone is co-administered. Risk of thyroid toxicity (both hypo- and hyperthyroidism), pulmonary toxicity, hepatotoxicity, and corneal microdeposits. Reassess at end-stage: if the primary goal of amiodarone is suppression of VT/VF and the ICD is being deactivated, amiodarone may still provide comfort by reducing the frequency of symptomatic arrhythmias. If the ICD remains active, amiodarone reduces inappropriate shocks.^[43]
Morphine SQ	Opioid / Dyspnea + Pain	2.5–5 mg SQ q4h + PRN	Essential in end-stage cardiomyopathy. Low-dose morphine is first-line for refractory dyspnea — reduces the sensation of breathlessness through central respiratory chemoreceptor modulation without clinically significant respiratory depression at these doses. Do not withhold in LVAD patients — dyspnea from right heart failure and pulmonary congestion is present regardless of LVAD function. Reduces preload (mild venodilation), which may provide additional hemodynamic benefit. Titrate to effect. CSCI (continuous subcutaneous infusion) at 10–20 mg/24h is effective for continuous dyspnea management.^[30]
Midazolam SQ	CRITICAL — LVAD DEACTIVATION	5–10 mg SQ/IV pre-deactivation	⚠ CAUTION: Primary comfort sedation agent for LVAD deactivation. Must be drawn up in a labeled syringe and confirmed at bedside BEFORE deactivation begins. Administer 15–30 minutes prior to pump cessation. Have additional 5 mg doses drawn and available for rescue every 10 minutes PRN for any agitation or distress post-deactivation. Do not begin deactivation until adequate sedation is confirmed. This medication is the difference between a peaceful death and preventable suffering.^[31]
Morphine (deactivation protocol)	Deactivation Sedation Adjunct	5–10 mg SQ/IV pre-deactivation	Given with midazolam before LVAD deactivation for dyspnea and pain prophylaxis. Administer 15–30 minutes prior. Have additional 5 mg rescue doses drawn and at bedside. Morphine addresses the air hunger and chest discomfort of cardiogenic shock; midazolam addresses the anxiety and agitation. Both are needed. Both must be pre-drawn. Continue rescue dosing as needed throughout the post-deactivation period until death.^[31]
Dobutamine or Milrinone	Comfort Inotrope	Dobutamine 2.5–5 mcg/kg/min CSCI	Palliative inotrope infusion for non-LVAD patients (or LVAD patients with severe right heart failure). No survival benefit — this is a comfort intervention. Improves cardiac output, reduces congestion, and dramatically improves quality of life in well-selected patients. Dobutamine via PICC or tunneled central line with ambulatory infusion pump. Milrinone preferred in patients on beta-blockers (mechanism independent of beta-receptors). Can be managed in the home setting with nursing support.^[29]
Tafamidis	TTR Stabilizer / ATTR-CM	61 mg daily	CONTINUE in hospice. Well-tolerated, oral, once daily, no significant drug interactions with any hospice medication. ATTR-ACT trial: 30% mortality reduction, 32% reduction in CV hospitalizations. Disease-modifying therapy that should not be stopped reflexively at hospice enrollment. Continue until the patient can no longer swallow or death is imminent (hours). Cost may be a barrier — engage pharmacy and social work for manufacturer assistance programs.^[4]
Lorazepam	Anxiolytic	0.5–1 mg PO/SQ q4–6h PRN	Anxiety is pervasive in LVAD patients — fear of device malfunction, alarm anxiety (especially nocturnal), anticipatory grief about deactivation, and existential distress. Lorazepam provides anxiolysis without significant hemodynamic effects. Sublingual route available if oral intake is compromised. Also useful for anticipatory grief responses in family members (with appropriate assessment). Can be combined with morphine for synergistic relief of anxiety-associated dyspnea.^[44]
Glycopyrrolate	Anticholinergic / Terminal Secretions	0.2 mg SQ q4h	End-stage management of terminal respiratory secretions ("death rattle"). Preferred over hyoscine (scopolamine) in conscious or semi-conscious patients because glycopyrrolate does not cross the blood-brain barrier — avoids the paradoxical agitation and hallucinations that hyoscine can cause in delirious patients. More effective when started early before secretions accumulate. Suctioning is rarely needed and can cause more distress than benefit.^[44]
Haloperidol	Antipsychotic / Delirium	0.5–1 mg PO/SQ q8h	Terminal delirium management in end-stage cardiomyopathy. Low cardiac output states produce metabolic encephalopathy — agitation, confusion, hallucinations, and restlessness. Haloperidol is first-line for hyperactive delirium. QTc prolongation risk — relevant in patients already on amiodarone or other QT-prolonging agents; use lowest effective dose. For refractory agitation, may escalate to midazolam or chlorpromazine. Avoid in patients with Parkinson's disease or Lewy body dementia.^[44]

🚨 Comfort Kit Must-Haves for This Diagnosis

Midazolam 5–10 mg SQ — LVAD deactivation primary sedation agent. Must be pre-drawn in a labeled syringe. This is not optional. A deactivation without pre-drawn midazolam at bedside should not proceed.
Morphine 5–10 mg SQ — Deactivation sedation adjunct + ongoing dyspnea management. Pre-drawn for deactivation; additional supply for routine comfort dosing.
Lorazepam 1 mg SQ — Anxiety, panic, alarm distress, anticipatory grief. Available for both patient and as-needed clinical situations.
Glycopyrrolate 0.2 mg SQ — Terminal secretion management. Start early when secretions begin — more effective as prophylaxis than treatment of established secretions.
Haloperidol 1 mg SQ — Terminal delirium. First-line for agitation and confusion in the final days.

For LVAD deactivation specifically: The full palliative sedation kit — midazolam, morphine, rescue doses of both, glycopyrrolate, and haloperidol — must be physically at the bedside, medications drawn up and labeled, BEFORE anyone touches the LVAD controller. This is a non-negotiable clinical standard. Confirm with the entire team. Confirm with the family. Then proceed.

S11 Clinician

Clinician Pointers

Eight field-tested clinical priorities for managing end-stage cardiomyopathy in hospice — from driveline inspection to ATTR-CM racial disparities to caregiver survival.

LVAD driveline care at every visit

Inspect the driveline exit site at every single visit without exception. You are looking for erythema, warmth, induration, purulent drainage, and tracking cellulitis along the subcutaneous tunnel. Driveline infection is the most common infectious complication of LVAD therapy and the leading cause of rehospitalization. It begins as localized erythema and progresses to deep tissue infection, bloodstream infection, and sepsis if not caught early. Culture any purulent drainage — Staphylococcus aureus (including MRSA) and Pseudomonas aeruginosa are the most common pathogens. Initiate targeted antibiotics based on culture results. For patients with chronic or recurrent driveline infections, suppressive antibiotics are a comfort measure — they are not curative (the driveline is a permanent foreign body), but they reduce the frequency of acute exacerbations and hospital transfers. Document the exit site appearance at every visit with a standardized description. Take photos with patient permission for trend monitoring.^[14]

LVAD alarm protocol must be in every room

A printed Red/Yellow/Green alarm response protocol must be posted in a visible location in every room where the patient spends time — bedroom, living room, and at minimum taped to the refrigerator. Every caregiver in the home — spouse, adult child, hired aide, respite volunteer — must demonstrate understanding of the alarm meanings and the correct response at every visit. Red alarms (power failure, low flow critical) require immediate action — battery change, controller check, 911 call if unresolved. Yellow alarms (low battery, speed deviation) require assessment and nurse notification. Green status means the device is functioning within parameters. Families who do not understand the alarms panic. Families who panic call 911 instead of following the protocol. That 911 call leads to an ER visit that could have been avoided with education and preparation. Review the protocol at every visit. Have the caregiver walk you through it verbally. "Show me what you would do if this alarm went off right now."^[2]

LVAD deactivation requires advance planning

LVAD deactivation is not a bedside procedure that can be improvised. It requires systematic advance planning: (1) Contact the LVAD coordinator at the implanting center — confirm the device type, the technical deactivation procedure, and whether the coordinator will be present in person or available by phone. (2) Prepare the palliative sedation protocol — midazolam and morphine ordered, drawn, labeled, at bedside; rescue doses prepared; glycopyrrolate available. (3) Prepare the family — they must understand what will happen when the pump stops, the expected timeline of death (minutes to hours), the physical changes they will witness (progressive hypotension, mottling, altered breathing, decreasing consciousness), and that the team will ensure their person feels no pain or distress. (4) Schedule the deactivation when the full team can be present — LVAD coordinator, hospice nurse, physician/NP, chaplain if desired, social worker if appropriate, and all family members who wish to be present. This is a planned, sacred, clinical event. Treat it with the gravity it demands.^[31]^[6]

Transplant delisting grief requires specific acknowledgment

Many patients enrolled in hospice with end-stage cardiomyopathy spent months or years on the UNOS transplant waitlist believing a new heart was coming. They carried a pager. They kept a packed hospital bag by the door. They endured repeated right heart catheterizations, panel-reactive antibody monitoring, and the psychological roller coaster of waiting for a call that never came — or that came and then was rescinded. Delisting is experienced as a death sentence, and it carries a grief that is specific, layered, and profound. The first layer is the loss of the transplant itself — the concrete hope of a new heart and a second chance. The second layer is the reason for delisting — which may carry shame (weight gain, substance use relapse, non-adherence) or the cruelty of a new diagnosis (cancer, renal failure) arriving on top of an already devastating disease. The third layer is the grief over the years spent hoping — the time invested in a future that will not materialize. The hospice team must name each of these layers. Sit down. Say: "I know you were being considered for a new heart, and that changed. That's a real loss, and I want to make sure we've talked about what that's meant to you." Then listen. Don't fix. Don't redirect. Listen.^[3]

ATTR-CM Val122Ile variant and racial disparity

The Val122Ile (V122I) variant of the transthyretin gene is present in approximately 3–4% of Black Americans — roughly 1.5 million carriers in the United States. It causes hereditary ATTR cardiac amyloidosis, typically manifesting as restrictive cardiomyopathy with heart failure after age 60. It is dramatically underdiagnosed — many patients are labeled as having "hypertensive heart disease" or "HFpEF of unclear etiology" and never receive the Tc-99m PYP scan or genetic testing that would identify ATTR-CM. This is a health equity failure of the first order. Even in hospice — even when the patient's own prognosis is terminal — the clinician who identifies this genetic variant in the family has done something that may save the lives of children and grandchildren. All first-degree relatives of a patient with hereditary ATTR-CM should be offered TTR gene testing. Carriers who test positive can begin cardiac surveillance with echocardiography and PYP scanning and, if amyloid deposition is detected, can start tafamidis before irreversible cardiac damage occurs. This is treatable disease caught in time. Ask about genetic testing. Facilitate the referral. Document the variant and the family notification plan in the chart. This may be the most consequential clinical act of the entire hospice enrollment.^[20]^[4]

VT storm management at end of life

Recurrent ICD shocks from ventricular tachycardia (VT) storm in end-stage cardiomyopathy is one of the most distressing end-of-life experiences for patients, families, and clinicians. Each ICD shock delivers 30–40 joules to the myocardium — the patient experiences a violent, painful jolt to the chest, often with a scream and a jump. Families who witness repeated shocks describe it as watching their loved one being tortured. When a patient has chosen comfort care, ICD deactivation is the most urgent device conversation — do not wait for another shock. ICD deactivation can be performed with a magnet placed over the device (temporary) or via programmer interrogation by an industry representative or electrophysiology team (permanent). Anti-tachycardia pacing (ATP) can be left active — it is painless and may terminate VT without a shock. For refractory VT causing hemodynamic instability or symptoms while awaiting ICD deactivation, IV amiodarone 150 mg bolus followed by infusion may suppress the arrhythmia. If shocks continue despite amiodarone, midazolam for comfort sedation is indicated immediately — the patient should not be conscious for repeated shocks.^[13]

Caregiver assessment is mandatory at every LVAD visit

The caregiver of an LVAD patient is performing a categorically different role than the caregiver of any other hospice patient. They are managing a medical device that sustains life: daily driveline site dressing changes with aseptic technique, continuous controller monitoring, battery charging and rotation every 10–14 hours, alarm response protocol execution, INR monitoring coordination, and the ever-present psychological awareness that a power failure, a driveline snag, or a controller malfunction could end their loved one's life. This is nursing care without nursing training. The caregiver burden literature in LVAD populations consistently shows elevated rates of PTSD, anxiety, depression, sleep disruption, and burnout — rates that exceed those of caregivers for cancer patients and approach those of caregivers for patients on home mechanical ventilation. Assess the caregiver separately at every visit. Ask them directly: "How are you doing with the device management?" That single question opens the conversation they desperately need but will not initiate on their own. Screen for depression. Screen for sleep disruption. Offer respite early and often — but understand that many LVAD caregivers refuse respite because no one else knows how to manage the device. That refusal is not stubbornness — it is rational fear. Help them train a backup caregiver.^[45]

Do not stop tafamidis reflexively at hospice enrollment

Tafamidis 61 mg daily for confirmed ATTR cardiac amyloidosis is disease-modifying therapy with Level A evidence (ATTR-ACT trial: 30% mortality reduction, 32% reduction in CV hospitalizations). It is well-tolerated — a single oral capsule taken once daily with no clinically significant drug interactions with opioids, diuretics, anticoagulants, benzodiazepines, or any other common hospice medication. It does not cause nausea, sedation, or any side effect that would impair quality of life. Stopping tafamidis as part of reflexive deprescribing at hospice enrollment is a clinical error. The drug should continue until the patient can no longer swallow or until death is imminent (hours to days) — and even then, the decision to stop should be an explicit goals-of-care conversation with the patient or surrogate, not a unilateral clinical decision. Cost is the primary barrier — tafamidis has a list price exceeding $200,000/year. Engage pharmacy and social work to explore manufacturer patient assistance programs (Pfizer's LVAD Assist program), copay cards, and insurance navigation. Do not let cost be the reason a patient loses access to effective, well-tolerated therapy at end of life.^[4]

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"I had a patient — LVAD, destination therapy, been on it two and a half years. His wife was meticulous. Driveline dressings every other day like clockwork. She could troubleshoot every alarm code on the controller from memory. She was the best LVAD caregiver I've ever seen. But one weekend the regular nurse was off, and the covering nurse didn't look at the driveline site. Just asked, 'How's everything going?' and the wife said fine. Two days later, I walked in for my visit and the exit site was angry — red, warm, tracking cellulitis running up his flank, purulent drainage soaking through the dressing. Temp was 101.4. He was septic within 36 hours. We cultured MRSA. Started vancomycin, suppressive doxycycline, got him stabilized — but he never fully recovered. Lost two months of quality time because nobody looked. The driveline site is not a checkbox on your visit form. It is the most vulnerable point on the patient's body. Lift the dressing. Look at it. Every visit. No exceptions."

— Waldo, NP · Terminal2

S12 Everyone Clinician

Psychosocial & Spiritual Care

Depression, LVAD-specific anxiety, transplant grief, deactivation ambivalence, caregiver identity, and the spiritual weight of choosing to turn off a machine that keeps the heart beating.

The psychosocial and spiritual dimensions of end-stage cardiomyopathy are among the most complex in all of hospice care. This is a population that has been living inside the medical system for years — often decades. They have undergone multiple hospitalizations, device implantations, medication titrations, and the sustained psychological burden of chronic life-threatening illness. Many have spent months on the transplant waitlist, carrying a pager and a packed bag, living in a state of hope-dependent hypervigilance. Some now carry an LVAD — a machine connected to their heart through a cable tunneling through their abdomen, powered by batteries they must change every 10 hours, monitored by a controller that alarms when something goes wrong. The psychological landscape is not generic "end-of-life distress" — it is a specific, layered architecture of technology dependence, lost hope, caregiver codependence, and the unique spiritual weight of a death that must be actively chosen through device deactivation. Every assessment, every intervention, and every conversation must account for this specificity.^[45]^[6]

Psychological Distress Screening

Depression in End-Stage Cardiomyopathy

Depression rates in advanced heart failure range from 40–50% — approximately double the rate in age-matched populations without heart failure and significantly higher than depression rates in many advanced cancers. In LVAD patients specifically, depression prevalence is 30–40%, with the highest rates in the first 3 months post-implant and again when complications accumulate or deactivation discussions begin. Depression in heart failure is not merely comorbid — it is pathophysiologically intertwined through neurohormonal activation (elevated catecholamines, cortisol), chronic inflammation (elevated IL-6, TNF-alpha), and cerebral hypoperfusion causing subclinical cognitive impairment.^[46]

Screening: PHQ-9 at admission and every 2 weeks. A score ≥10 warrants treatment initiation. In LVAD patients, somatic items (fatigue, sleep disruption, appetite changes) overlap heavily with heart failure symptoms — focus on cognitive-affective items (anhedonia, hopelessness, guilt, worthlessness) for more specific screening.

Treatment: Mirtazapine is first-line in end-stage cardiomyopathy — it addresses depression, anxiety, insomnia, and anorexia simultaneously (appetite stimulation and sedation are therapeutic, not side effects, in this population). Start 7.5–15 mg QHS. SSRIs are second-line — sertraline has the best cardiac safety data (SADHART trial). Avoid tricyclics (QTc prolongation, arrhythmia risk). Avoid venlafaxine (hypertension). Psychotherapy (CBT, dignity therapy) should be offered concurrently when the patient has cognitive capacity and willingness.^[46]

Anxiety, PTSD, and LVAD-Specific Distress

LVAD patients have uniquely elevated rates of anxiety disorders and PTSD. The sources are specific and identifiable: alarm anxiety — the controller emits audible alarms for power failures, low flow states, and battery depletion, and these alarms are designed to be impossible to ignore; many patients and caregivers develop conditioned anxiety responses to any electronic beeping sound; nocturnal alarms are particularly devastating to sleep and psychological well-being. Device dependence anxiety — the constant awareness that a mechanical failure, a battery depletion, or a driveline disconnection could cause death within minutes. Body image distress — the driveline exit site, the controller bulge, the inability to shower normally or swim, and the visible evidence of medical technology integrated into the body. PTSD from prior ICD shocks — patients who have experienced ICD shocks describe them as being "kicked in the chest by a horse" and develop hypervigilance and avoidance behaviors.^[45]

Screening: GAD-7 at admission and every 2 weeks. PCL-5 (PTSD Checklist) if ICD shocks or LVAD-related traumatic events are reported. Screen caregivers separately — caregiver PTSD rates approach 30% in LVAD populations.

Treatment: Lorazepam 0.5–1 mg PRN for acute anxiety and alarm distress. Mirtazapine for comorbid anxiety-depression. Behavioral interventions: alarm response rehearsal (reduces anxiety through procedural confidence), relaxation training, and mindfulness-based stress reduction adapted for LVAD patients. Normalize the fear — "It makes complete sense that you're anxious about this device. It's keeping your heart going. Anyone would feel that way."

LVAD Caregiver Identity and Burden

The caregiver of an LVAD patient occupies a role that exceeds what any family member should be asked to bear. They are performing daily sterile driveline dressing changes, monitoring a controller that alarms unpredictably, managing battery charging schedules, coordinating INR monitoring, and maintaining constant vigilance against device complications — responsibilities that in a hospital setting would be distributed across a team of ICU nurses. The literature consistently documents elevated rates of depression (35–45%), anxiety (40–50%), sleep disruption (60–70%), and caregiver burnout in LVAD caregivers, with rates that exceed those reported for caregivers of patients with cancer, dementia, or other chronic illnesses.^[45]

The caregiver's identity often becomes inseparable from the device management role. They are not just "caring for a sick spouse" — they are the person who keeps the machine running. This creates a psychological bind at end of life: agreeing to LVAD deactivation means not just losing their person but surrendering the role that has defined their daily existence for months or years. They may experience deactivation as a personal failure — "I was supposed to keep the machine going, and now I'm agreeing to turn it off." The hospice team must assess the caregiver separately at every visit. The opening question is simple and powerful: "How are you doing with the device management?" That question — specific, non-judgmental, acknowledging the technical reality of their role — opens the conversation they desperately need but will not initiate on their own.

Transplant Grief

For patients who were on the transplant waitlist and were delisted, the grief is specific, layered, and requires targeted intervention — not generic comfort language. There are three distinct layers that must be named individually:

Layer 1 — Grief about the lost new heart: The transplant was not an abstraction. It was a specific, concrete hope — a new organ, a second chance, a future measured in decades rather than months. The patient may have attended pre-transplant education classes, met transplant recipients who told their stories of recovery, and imagined a life after transplant. That future is gone.

Layer 2 — Grief about the reason for delisting: The reason for delisting may carry shame. Weight gain beyond BMI limits. A substance use relapse. Non-adherence with medical appointments or medications. Or the cruelty of a new diagnosis — cancer discovered on surveillance imaging, progressive renal failure, a stroke that caused new cognitive impairment — arriving on top of an already devastating disease. The patient may feel responsible for their delisting, even when the cause was entirely beyond their control.

Layer 3 — Grief over the years spent hoping: Months or years of life organized around the transplant — the pager on the nightstand, the packed bag by the door, the dietary restrictions, the repeated cardiac catheterizations, the PRA monitoring, the waiting. That investment of time, suffering, and hope did not yield the promised return. The time cannot be recovered.

The hospice team must name each layer explicitly. A single acknowledgment — "I'm sorry you didn't get the transplant" — is insufficient. Sit with the patient. Name what was lost. "You were waiting for a new heart. That was a real hope, not a fantasy. And then it was taken away. I want to understand what that's been like for you." Allow silence. Allow anger. Allow the grief to be as large as it actually is.

Spiritual Assessment

The spiritual dimensions of end-stage cardiomyopathy are shaped by the unique intersection of technology, mortality, and the meaning of the heart in human culture and faith. The heart is not just an organ — it is the universal symbol of life, love, soul, and identity. A failing heart carries symbolic weight that a failing liver or kidney does not. And for LVAD patients, the spiritual landscape includes an additional layer: the meaning of living on a machine, the question of whether mechanical life is "real" life, and the spiritual implications of choosing to turn the machine off.^[47]

Key spiritual themes in end-stage cardiomyopathy:

The meaning of mechanical life support: "Am I really alive, or is the machine alive?" Patients with LVADs — particularly those who have been on the device for years — may question whether their life has authentic meaning when it depends entirely on a mechanical pump. Faith traditions that emphasize God's sovereignty over life and death may struggle with the theological implications of a machine sustaining the heartbeat.
Deactivation and God's plan: For patients from faith traditions that view life as sacred and death as God's prerogative, the decision to deactivate an LVAD can create profound spiritual crisis. "Am I playing God by turning it off? Am I playing God by keeping it on?" Both questions are valid. The chaplain's role is not to resolve the paradox but to sit with the patient inside it.
The heart as identity: "My heart is failing. Does that mean I am failing?" The symbolic equation of heart with self — with courage, with love, with character — can make cardiac disease feel like a failure of the person, not just the organ. This is especially true for men socialized to associate cardiac strength with masculine identity.
Legacy and completion: Many patients with end-stage cardiomyopathy have known their prognosis for years. They have had time to think about legacy, meaning, and what they want to leave behind. Dignity therapy (Chochinov protocol) is particularly powerful in this population — the structured interview about life history, values, and messages for loved ones gives the patient an opportunity to create a permanent document of their meaning.

01

Offer chaplaincy at admission and at every transition point — not as a checkbox, but as a genuine invitation. "We have a chaplain on our team who has experience with patients on heart devices. Would it be helpful to have them visit? They're not here to push any particular belief — they're here to listen and to help you think through the things that matter most to you." Revisit the offer at each transition: when deactivation conversations begin, when the patient enters the pre-active phase, and on the day of deactivation itself.
02

Screen for spiritual distress using the FICA tool — Faith/belief, Importance/influence, Community, Address/action. In LVAD patients, add specific questions: "Has living on this device affected how you think about your life or your faith?" and "When you think about the device being turned off someday, what comes up for you spiritually?" These questions may surface deep ambivalence, fear, or spiritual suffering that generic screening will miss.
03

Respect deactivation ambivalence as spiritually and psychologically healthy. A patient who says "I'm not ready yet" is not in denial — they are navigating an extraordinarily complex decision that intersects medical reality, spiritual belief, family dynamics, and existential meaning. Do not rush. Do not frame continued LVAD use as "prolonging suffering." Allow the patient to arrive at their decision in their own time, with support, information, and companionship. The decision may come suddenly, or it may evolve over weeks. Both timelines are valid.
04

Address the caregiver's spiritual needs independently. The spouse who has been managing the LVAD for two years is not just a caregiver — they are a co-patient in the spiritual sense. They carry their own grief, their own guilt, their own questions about meaning. "Did I do enough?" "Should I have agreed to this device?" "Am I a bad person for wanting this to be over?" These questions need space that is separate from the patient's bedside. Offer chaplaincy and counseling to the caregiver directly.

Goals-of-Care Communication

Opening the LVAD Deactivation Conversation

The LVAD deactivation conversation is the most consequential goals-of-care discussion in cardiology hospice care. It must be framed correctly from the first sentence. The wrong framing can shut down the conversation for weeks; the right framing creates space for authentic exploration.

Effective framing:

"As things get harder, I want to make sure you and your family have had a chance to think about all your options — including what you want to happen with the device."
"Some patients at this point in their illness decide they want to focus entirely on being comfortable and being with their family, and that might include turning off the device when the time feels right. Other patients choose to keep it running. Both are completely valid choices. What matters is that you've had time to think about it."
"Turning off the device is not giving up. It's choosing peace. It's choosing to let your heart rest. And if that's what you decide, we will make sure you feel no pain and that your family is with you."

Key principle: Never frame deactivation as "giving up," "letting go," or "stopping the fight." Frame it as choosing comfort, choosing peace, choosing to be present with family without the burden of the device. The language of war metaphors — fighting, battling, losing — is particularly harmful in this population because it implies that continuing the LVAD is brave and deactivating is cowardly. Both are brave. Both are valid. Both deserve respect.^[6]

Communication Pitfalls

"Have you thought about turning off the pump?" — Too abrupt. Too clinical. Opens with a yes/no question that allows the patient to shut down the conversation immediately. The answer will be "no" or silence, and you've lost the opening.
"The device is just prolonging your suffering." — Imposes the clinician's value judgment on the patient's experience. Many LVAD patients do not experience the device as suffering — they experience it as life. They may be right. They get to decide.
"It's time to let go." — Vague, patronizing, and invalidating. "Let go" of what? The device? Hope? Life? This phrase means nothing specific and communicates everything the patient fears: that you think they should be dead already.
Talking to the family about deactivation without the patient present (when the patient is competent). — This is an autonomy violation. The patient makes this decision. The family supports the patient's decision. Do not circumvent the patient by building family consensus first. If the family initiates the conversation without the patient, redirect: "This is such an important decision. Can we make sure [patient] is part of this conversation?"
Waiting for the cardiologist to initiate the conversation. — The cardiologist may never initiate it. They are trained to escalate, optimize, and intervene — not to withdraw. The hospice team owns this conversation. Waiting for permission from cardiology is a barrier to timely, goal-concordant care.
Conflating LVAD deactivation with ICD deactivation. — These are fundamentally different decisions with different consequences. ICD deactivation removes a safety net against arrhythmic death but does not directly cause death. LVAD deactivation causes death from cardiogenic shock within minutes to hours. Families must understand this distinction clearly.

Suicidal Ideation

Suicidal ideation in end-stage cardiomyopathy must be screened for explicitly and managed with the same clinical urgency as in any other population. The risk factors are compounded: chronic pain, refractory dyspnea, functional limitation, social isolation, depression rates of 40–50%, sleep disruption, medication side effects, and the existential weight of living on a machine or awaiting a transplant that will never come. LVAD patients face an additional risk factor: they have direct access to a lethal mechanism — disconnecting the device or manipulating the controller would cause death. This is not a theoretical concern; case reports of LVAD patients deliberately disconnecting their devices have been published.^[46]

Screen with Item 9 of the PHQ-9 at every assessment: "Over the last 2 weeks, how often have you been bothered by thoughts that you would be better off dead, or of hurting yourself?" Any positive response requires immediate follow-up: frequency, plan, intent, access to means. For LVAD patients, "access to means" includes the device itself — assess whether the patient has expressed any intention to manipulate or disconnect the LVAD outside of a planned, supported deactivation process.

Critical distinction: A patient who requests LVAD deactivation through the proper informed consent process — with decision-making capacity, understanding of the consequences, and the support of their clinical team and family — is not expressing suicidal ideation. They are exercising their autonomous right to withdraw a life-sustaining treatment. This is ethically, legally, and clinically distinct from suicidal intent. Do not conflate the two. Do not pathologize the deactivation request. But do assess carefully: if the request emerges suddenly in the context of acute depression, psychotic symptoms, or impulsive distress, capacity evaluation and psychiatric consultation are appropriate before proceeding.

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"The patients who worry me most about the deactivation conversation aren't the ones who are angry or crying or arguing with their family. Those patients are processing. They're doing the work. The ones who worry me are the ones who are very quiet. The ones who nod when you explain the options and say 'whatever you think is best' and then stare at the ceiling. Those patients are in spiritual agony. They've been fighting this disease for years. They've endured the surgeries, the hospitalizations, the device implantation, the driveline infections, the transplant list, and the delisting. And now they're being asked to make one more decision — the last one — and they have nothing left. No fight, no hope, no anger, no tears. Just silence. When I see that silence, I pull up a chair. I don't ask questions. I don't offer options. I just sit with them. Sometimes for a long time. And eventually, one of two things happens: they start talking, or they fall asleep. Either one is okay. Because what they need in that moment is not information or a decision framework. What they need is someone who is willing to be in the room with them while they carry something that no human being should have to carry alone."

— Waldo, NP · Terminal2

S13 Family Everyone

Family Guide

Practical guidance for families caring for a loved one with end-stage cardiomyopathy — especially those managing an LVAD at home. What to watch for, what to do, and when to call.

If your loved one has an LVAD — a left ventricular assist device — you already know that caring for them at home is unlike anything you ever imagined. You are managing a medical device that keeps their heart pumping. You change sterile dressings on the cable that exits their abdomen. You charge and swap batteries every day. You know what each alarm sound means and what to do when you hear it. You have been doing this for weeks, months, maybe years. And you have been doing it with a level of dedication and skill that most trained nurses would admire. This section is for you — to help you know what to watch for as things change, what you can do to help, and when to call the hospice team. You are not alone in this. We are your partners, and we are here every step of the way.

What You May See

LVAD controller alarms
The controller will sound alarms when something needs attention. Red alarms are emergencies — they mean power failure, critically low flow, or device malfunction and require immediate action per your protocol (check connections, swap battery, call the LVAD coordinator or 911 if unresolved). Yellow alarms mean something needs assessment — a low battery warning, a speed change, or a minor deviation — and you should call your hospice nurse for guidance. Know your alarm protocol. Have it posted. Review it regularly with your hospice team. A Red alarm in the middle of the night is terrifying — knowing exactly what to do makes it manageable.^[2]
Driveline exit site changes
The cable (driveline) that comes out of your loved one's abdomen connects the internal pump to the external controller. Where it exits the skin is a permanent opening that can become infected. Watch for redness around the exit site, swelling, warmth to the touch, or any drainage — especially drainage that is thick, cloudy, or has an odor. If you notice any of these changes, call the hospice nurse the same day. Do not wait for the next scheduled visit. Early treatment of driveline infections prevents them from becoming serious.^[14]
Battery warnings and power management
The LVAD runs on batteries during the day and plugs into wall power at night. Always have two fully charged backup batteries ready at all times. A power failure — whether from dead batteries or an unplugged wall connection — stops the pump. There is no grace period. Battery management is a daily routine: charge, check, rotate, and always know where the backups are. If your area is prone to power outages, discuss an emergency power plan with your hospice team.^[2]
Increased fatigue and breathlessness despite the device
Even with the LVAD supporting the left side of the heart, the right side of the heart can continue to weaken over time. This means your loved one may gradually become more tired, more short of breath, and less able to do the things they could do when the device was first implanted. This is expected progression of the disease — it does not mean the device is failing. The hospice team can adjust medications to help with these symptoms.^[5]
Cheyne-Stokes periodic breathing during sleep
You may notice a pattern during sleep where your loved one's breathing gradually speeds up, then slows down, then pauses for several seconds before the cycle starts again. This is called Cheyne-Stokes respiration, and it is common in advanced heart failure. It can be alarming to watch — the pauses can last 10–20 seconds and may look like your loved one has stopped breathing. But they will start again. This pattern does not mean they are suffocating or in pain. Tell your hospice nurse about it, but know that it is a recognized part of advanced heart disease.^[7]
Severe fluid retention
Swollen legs, swollen ankles, a swollen and tight abdomen, sudden weight gain of several pounds in a day or two — these are signs that fluid is building up because the heart cannot pump effectively enough to keep the kidneys clearing fluid. This causes discomfort, difficulty breathing, and difficulty moving. Report any sudden weight gain (more than 2–3 pounds in a day) or new swelling to the hospice nurse. Medications can often help reduce the fluid and improve comfort.

How You Can Help

Practice alarm response protocol until it is automatic
Practice matters. Walk through the alarm response protocol with your hospice nurse until you can do it without thinking — because at 3 AM when the alarm goes off and your heart is pounding, you will not be able to think clearly. Muscle memory takes over. Check batteries, check connections, swap if needed, call the number. Practice it like a fire drill. Ask every family member who stays in the home to learn it too. The more people who know the protocol, the safer your loved one is.
Maintain consistent battery charging and backup readiness
Make battery management part of your daily routine — as automatic as brushing your teeth. Charge batteries at the same time every day. Always have two full backups ready. Check the charge level before bed. Keep the wall power cable plugged in and accessible. Label the backup batteries with tape so you can tell which ones are freshly charged. A consistent routine prevents the panic of discovering dead batteries when you need them most.
Keep the driveline secure and dry
The driveline cable is the most vulnerable point on the device system. Prevent it from being tugged, pulled, or caught on anything — clothing, furniture, doorknobs, pet leashes. Secure it against the body with a driveline stabilization belt or abdominal binder. Keep the exit site dry — no submerging in water, no swimming, no soaking in a bath. Follow the dressing change protocol your LVAD team taught you, and ask your hospice nurse if you need a refresher.
Know that the deactivation conversation has been or will be had
At some point, the hospice team will talk with you and your loved one about what you want to happen with the device as things progress. This is not a sign that something is wrong right now — it is planning for the future so that your loved one's wishes are known and honored. You have a voice in this conversation. Your perspective matters. And there is no wrong answer. Some families choose to continue the device until natural death; others choose a planned, peaceful deactivation surrounded by family. Both choices are respected and supported.
Keep a symptom diary
Write down daily: weight (same time each morning, after using the bathroom, before eating), swelling observations, shortness of breath level (better, same, worse), how they slept, appetite, and any new symptoms. This diary is incredibly valuable to the hospice team — it helps us see trends that a single visit cannot capture. A simple notebook by the bedside is all you need. Bring it to every nurse visit or have it ready when we call.
Take care of yourself
This is not a platitude. You are performing complex medical care — sterile dressing changes, device monitoring, alarm response, medication management — without the training, the shift changes, or the emotional distance that hospital nurses have. You are doing this because you love someone, and that love does not protect you from exhaustion, anxiety, depression, or burnout. Call us. Tell us how you are doing — honestly. Accept respite care when it is offered. Ask for help training a backup person who can give you a night off. You cannot care for your loved one if you collapse. Your well-being is not secondary to theirs — it is essential to theirs.

📞 Call the Hospice Nurse Immediately If:

Red alarm with no response after troubleshooting — You've checked the connections, swapped the battery, followed the protocol, and the Red alarm persists. Call the hospice nurse and the LVAD coordinator number you were given. If you cannot reach either within minutes, call 911.
Sudden confusion, slurred speech, or one-sided weakness — These are signs of a stroke, which LVAD patients are at higher risk for. This is a medical emergency. Call 911 immediately. Tell the dispatcher your loved one has an LVAD.
New or worsening redness, drainage, or fever at the driveline site — Any temperature above 100.4°F (38°C) combined with driveline site changes suggests infection. Call the hospice nurse the same day. Do not wait for the next visit.
Controller showing persistent low flow or power alarms — Persistent low flow alarms may indicate a pump problem, dehydration, or a change in heart function. Persistent power alarms indicate a battery or electrical issue. Both require nurse assessment.
Sudden severe shortness of breath — New or dramatically worsened shortness of breath — especially if the patient cannot speak in full sentences, is breathing rapidly, or is sitting bolt upright and refusing to lie down — requires immediate nurse assessment. This may indicate fluid overload, a new arrhythmia, or a change in device function.
Battery failure with no backup available — If the current batteries are dying and you have no charged backup, this is an emergency. Plug into wall power immediately. If no wall outlet is accessible, call 911. The pump cannot run without power.

💛 For You, the Caregiver

Being the caregiver of an LVAD patient is one of the most demanding roles in all of hospice care. You are not just watching over someone who is sick — you are managing a medical device that keeps your person alive. Every day, you change dressings, monitor alarms, charge batteries, and carry the weight of knowing that your vigilance matters in a way that most people will never understand. That takes extraordinary courage and daily discipline. We see it. We respect it. And we want you to know: you do not have to carry this alone. We are here — not just for your loved one, but for you. Call us. Lean on us. Let us help you carry what you've been carrying by yourself.

S14 Everyone

Waldo's Top 10 Tips

Ten field-tested priorities for end-stage cardiomyopathy — from LVAD deactivation planning to ATTR-CM genetic vigilance to the loneliest alarm in hospice.

1

Initiate the LVAD deactivation conversation yourself. Do not wait for the cardiologist to bring it up — they may never bring it up. Do not wait for the LVAD coordinator — they are focused on device optimization, not end-of-life planning. Do not wait for the family to ask — they are terrified and don't know how to start. You start it. Sit down. Make eye contact. And say: "Have you and your family talked about what you want to happen with the device as things get harder?" That's it. That one sentence opens the door. You don't have to walk through it today. But you opened it. And once it's open, the patient knows they have permission to think about it, talk about it, and eventually — when they're ready — decide. The worst deactivation I ever managed was one where nobody had the conversation until the patient was actively dying and the family was in crisis. The best was one where we talked about it over three visits, planned it together, and the patient chose the day, chose the music, and held his wife's hand when the pump stopped. That's the difference between a conversation initiated and a conversation avoided.^[6]
2

Prepare the palliative sedation protocol before the LVAD deactivation — not during it. Midazolam and morphine must be drawn up, labeled in syringes, confirmed at the bedside, and rescue doses prepared BEFORE anyone touches the LVAD controller. I cannot say this more clearly: a patient who experiences cardiogenic shock without pre-sedation is suffering that you caused by not preparing. The pump stops. Blood pressure drops. Air hunger begins. Agitation follows. If you are scrambling to open vials and draw up medications at that moment, you have failed the most important clinical moment of this patient's life. Draw the midazolam. Draw the morphine. Label them. Lay them on the bedside table. Confirm with your team. Then — and only then — proceed. The difference between a peaceful death and a traumatic one is 15 minutes of preparation.^[31]
3

Inspect the driveline exit site at every single visit. I don't care if you're there for a medication review. I don't care if the visit is running long and you're already behind. I don't care if the caregiver says "it looks fine." Lift the dressing. Look at the site. Document what you see. Because a driveline infection that is caught at the erythema stage — a little redness, a little warmth — can be managed with oral antibiotics and suppressive therapy. A driveline infection that is ignored for a week because nobody looked becomes tracking cellulitis, then deep tissue infection, then bloodstream infection, then sepsis, then a hospital transfer that could have been prevented. Culture early. Treat early. Suppress chronically. Suppressive antibiotics in a patient with a chronic driveline infection are not curative — they are a comfort measure, and they work. The driveline site is the Achilles heel of every LVAD patient. Treat it that way.^[14]
4

Transplant delisting grief is specific and devastating, and it requires a specific response. Don't say "I'm sorry." Don't say "everything happens for a reason." Don't say "at least you had time with your family." Sit down. Look at them. And say: "I know you were being considered for a new heart, and that changed. I want to make sure we've talked about what that meant to you." Then listen. Really listen. Because what they lost was not abstract. They lost the pager that might ring at 2 AM with the call that would save their life. They lost the packed bag by the door. They lost the transplant coordinator who knew their blood type and their antibody profile and their name. They lost a future — a specific, imagined future with decades in it. And then they were told, in a meeting that lasted 30 minutes, that the future was no longer available. Some of them were delisted for reasons that carry shame — weight gain, substance use, non-adherence. Some were delisted because cancer showed up on a scan, or their kidneys failed, or they had a stroke. None of them deserved it. Name the grief. All three layers of it. And let them be angry if they need to be.^[3]
5

ATTR-CM tafamidis does not stop at hospice enrollment. I've seen it happen — a patient with confirmed transthyretin cardiac amyloidosis, doing reasonably well on tafamidis 61 mg daily, enrolls in hospice for support, and someone reflexively stops the tafamidis because "we're deprescribing." That is a clinical error. Tafamidis is disease-modifying therapy backed by Level A evidence — the ATTR-ACT trial showed a 30% mortality reduction and a 32% reduction in cardiovascular hospitalizations. It is well-tolerated, oral, once daily, and has zero clinically significant interactions with opioids, benzodiazepines, diuretics, or anticoagulants. It is one of the cleanest drugs in all of cardiology. Stop it only with an explicit goals-of-care conversation and a documented patient choice — not as a line item on a deprescribing checklist. Continue it until the patient can no longer swallow. If cost is the barrier, engage social work and pharmacy to explore manufacturer assistance. Do not let a patient lose access to effective therapy because of a reflex.^[4]
6

The LVAD caregiver is performing nursing care without nursing training, and they are not okay. They are doing sterile dressing changes every 48 hours. They are monitoring a controller that alarms at 3 AM. They are charging and swapping batteries on a schedule that never takes a day off. They are watching for signs of infection, stroke, bleeding, and device malfunction — and they are doing all of this while grieving the person they are losing. The literature says 35–45% depression, 40–50% anxiety, and caregiver PTSD rates approaching 30% in LVAD populations. In my experience, those numbers are low. Assess the caregiver separately at every visit. Not in front of the patient — separately. And the question is simple: "How are you doing with the device management?" That question — specific, not generic — opens the conversation they desperately need but will never initiate. Because they believe their job is to be strong. Their job is not to be strong. Their job is to be supported. That's your job.^[45]
7

ICD shocks at end of life are torture, and every one of them after a comfort decision has been made is your responsibility to prevent. I have watched a dying man get shocked six times in his last 12 hours because nobody deactivated the ICD. Each shock — 30 to 40 joules directly to the myocardium — made him scream, made his body convulse, and made his wife collapse in the corner of the room sobbing. That is not dying with dignity. That is being assaulted by your own implanted device while your family watches. When a patient has chosen comfort care, ICD deactivation is the most urgent device conversation you will have. Do not wait for the electrophysiologist to return your call. Place a magnet over the device immediately — that suspends shock therapy as long as the magnet is in place. Then arrange permanent deactivation via programmer interrogation. If the patient is still having symptomatic VT, amiodarone IV for suppression and midazolam for comfort. But get that ICD turned off. Today. Not tomorrow. Today.^[13]
8

The ATTR-CM Val122Ile variant in Black Americans is underdiagnosed to a degree that should embarrass American cardiology. Approximately 3–4% of Black Americans carry this variant — roughly 1.5 million people. It causes hereditary transthyretin cardiac amyloidosis, typically presenting as restrictive cardiomyopathy with heart failure after age 60. Most carriers are never tested. Most are labeled "hypertensive heart disease" or "HFpEF" and never receive the PYP scan or genetic test that would reveal the true diagnosis. If your hospice patient has ATTR-CM — wild-type or hereditary — ask whether genetic testing has been done. If the patient carries Val122Ile, every first-degree relative should be offered TTR gene testing. Positive carriers can begin surveillance and, if amyloid deposition is detected, start tafamidis before the heart is irreversibly damaged. You may be in hospice caring for a dying patient, but the genetic counseling referral you initiate today could save the life of their 55-year-old daughter who has been told her shortness of breath is "just her weight." That is not hyperbole. That is the clinical reality of hereditary ATTR-CM.^[20]
9

The LVAD alarm at 3 AM is the loneliest sound in hospice caregiving. The house is dark. The caregiver is exhausted. The alarm pierces the silence — a high-pitched, insistent tone that the brain cannot ignore because it was designed to be impossible to ignore. The caregiver jolts awake, heart pounding, and in that first disoriented second, everything they were ever afraid of floods in: Is the battery dead? Is the pump failing? Is he dying right now? This happens night after night, week after week, month after month. And it changes people. It gives them insomnia. It gives them anxiety that bleeds into the daylight hours. It makes them flinch at the sound of a microwave beeping or a car alarm in a parking lot. Prepare the family for it. Rehearse the alarm response until it is automatic. Walk them through it at 10 AM on a Tuesday when everyone is calm, so that at 3 AM on a Thursday when everyone is terrified, the protocol takes over. And here is the clinical truth: a family member who panics at a Red alarm and calls 911 instead of following the protocol has not been prepared adequately. That 911 call — the ambulance, the ER, the chaos — that is on us. We did not prepare them well enough. Do better. I'm talking to myself, too.^[2]
10

The LVAD deactivation death — when it is planned, prepared, and surrounded by people who love the patient — can be one of the most profoundly peaceful deaths in all of hospice care. I have been part of deactivations that I will carry with me for the rest of my career. The family gathered. The chaplain prayed. The patient, sedated and comfortable, held his daughter's hand. The LVAD coordinator walked us through the procedure by phone. The nurse confirmed the midazolam and morphine were on board. The pump speed was reduced to zero. The alarms sounded — and then were silenced. The room was quiet except for the breathing, which gradually slowed, and the family's voices telling him they loved him. He died 40 minutes later without a grimace, without a gasp, without a moment of distress. His wife told me afterward: "That was exactly what he wanted. He wanted to go home to God on his own terms, with us beside him." That is the standard. Not the exception — the standard. A planned, prepared, peaceful death achieved through clinical excellence and human presence. Every LVAD deactivation should look like that. And when it does, you will know that you practiced medicine at its highest form — not curing disease, but honoring the person inside it.^[6]^[31]

— Waldo, NP ·

REFClinician

References

Peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.

McNally EM, Mestroni L. Dilated cardiomyopathy: genetic determinants and mechanisms. Circ Res. 2017;121(7):731-748.

PMID 28912180 DOIReview

Herman DS, Lam L, Taylor MR, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012;366(7):619-628.

PMID 22335739 DOIObservational

van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers: a European cohort study. J Am Coll Cardiol. 2012;59(5):493-500.

PMID 22281253 DOIObservational

O'Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J. 2014;35(30):2010-2020.

PMID 24126876 DOIObservational

Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114(3):216-225.

PMID 16831987 DOIObservational

Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404-2412.

PMID 27143678 DOIObservational

Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007-1016.

PMID 30145929 DOIRCT

González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585-2594.

PMID 26224076 DOIObservational

Quarta CC, Buxbaum JN, Shah AM, et al. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med. 2015;372(1):21-29.

PMID 25551524 DOIObservational

Mehra MR, Uriel N, Naka Y, et al. A fully magnetically levitated left ventricular assist device — final report. N Engl J Med. 2019;380(17):1618-1627.

PMID 30883052 DOIRCT

Kirklin JK, Pagani FD, Kormos RL, et al. Eighth annual INTERMACS report: special focus on framing the impact of adverse events. J Heart Lung Transplant. 2017;36(10):1080-1086.

PMID 28942782 DOIObservational

Rogers JG, Pagani FD, Tatooles AJ, et al. Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med. 2017;376(5):451-460.

PMID 28146651 DOIRCT

Kirklin JK, Naftel DC, Myers SL, Pagani FD, Colombo PC. Quantifying the impact from stroke during support with continuous flow ventricular assist devices: an STS INTERMACS analysis. J Heart Lung Transplant. 2020;39(8):782-794.

PMID 32376278 DOIObservational

Draper KV, Huang RJ, Gerson LB. GI bleeding in patients with continuous-flow left ventricular assist devices: a systematic review and meta-analysis. Gastrointest Endosc. 2014;80(3):435-446.e1.

PMID 24975405 DOIMeta-Analysis

Goldstein DJ, Naftel D, Holman W, et al. Continuous-flow devices and percutaneous site infections: clinical outcomes. J Heart Lung Transplant. 2012;31(11):1151-1157.

PMID 22766022 DOIObservational

McIlvennan CK, Grady KL, Matlock DD, et al. End of life for patients with left ventricular assist devices: insights from INTERMACS. J Heart Lung Transplant. 2019;38(4):374-381.

PMID 30642799 DOIObservational

Fang JC, Ewald GA, Allen LA, et al. Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee. J Card Fail. 2015;21(6):519-534.

PMID 25953697 DOIGuideline

Lampert R, Hayes DL, Annas GJ, et al. HRS expert consensus statement on the management of cardiovascular implantable electronic devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy. Heart Rhythm. 2010;7(7):1008-1026.

PMID 20471915 DOIGuideline

Rogers JG, Patel CB, Mentz RJ, et al. Palliative care in heart failure: the PAL-HF randomized, controlled clinical trial. J Am Coll Cardiol. 2017;70(3):331-341.

PMID 28705314 DOIRCT

Ekström M, Nilsson F, Abernethy AA, Currow DC. Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease: a systematic review. Ann Am Thorac Soc. 2015;12(7):1079-1092.

PMID 25803110 DOISystematic Review

Olivotto I, Oreziak A, Baez-Escudero JL, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759-769.

PMID 32871100 DOIRCT

Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-eighth adult heart transplantation report — 2021. J Heart Lung Transplant. 2021;40(10):1035-1049.

PMID 34419370 DOIObservational

Colvin M, Smith JM, Hadley N, et al. OPTN/SRTR 2011 annual data report: heart. Am J Transplant. 2013;13(Suppl 1):119-148.

PMID 23237699 DOIObservational

Stevenson LW, Pagani FD, Young JB, et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant. 2009;28(6):535-541.

PMID 19481012 DOIObservational

McIlvennan CK, Jones J, Allen LA, et al. Bereaved caregiver perspectives on the end-of-life experience of patients with a left ventricular assist device. JAMA Intern Med. 2016;176(4):534-539.

PMID 26999575 DOIObservational

Pedersen CT, Kay GN, Kalman J, et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Heart Rhythm. 2014;11(10):e166-e196.

PMID 25179489 DOIGuideline

Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12(8):767-778.

PMID 20675664 DOIGuideline

Kindermann I, Barth C, Mahfoud F, et al. Update on myocarditis. J Am Coll Cardiol. 2012;59(9):779-792.

PMID 22361396 DOIReview

Guzzo-Merello G, Cobo-Marcos M, Gallego-Delgado M, Garcia-Pavia P. Alcoholic cardiomyopathy. World J Cardiol. 2014;6(8):771-781.

PMID 25228956 DOIReview

Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Heart Rhythm. 2011;8(8):1308-1339.

PMID 21787999 DOIGuideline

Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014;2(6):641-649.

PMID 25282031 DOIRCT

Holubarsch CJF, Colucci WS, Meinertz T, Gaus W, Tendera M. The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial. Eur J Heart Fail. 2008;10(12):1255-1263.

PMID 19019730 DOIRCT

DiNicolantonio JJ, Niazi AK, Lavie CJ, O'Keefe JH, Ventura HO. Thiamine supplementation for the treatment of heart failure: a review of the literature. Congest Heart Fail. 2013;19(4):214-222.

PMID 23910704 DOIReview

Hashim T, Sanam K, Engel M, et al. Clinical characteristics and outcomes of intravenous inotropic therapy in advanced heart failure. Circ Heart Fail. 2015;8(5):880-886.

PMID 26179184 DOIObservational

Kerrigan DJ, Williams CT, Ehrman JK, et al. Cardiac rehabilitation improves functional capacity and patient-reported health status in patients with continuous-flow left ventricular assist devices: the Rehab-VAD randomized controlled trial. JACC Heart Fail. 2014;2(6):653-659.

PMID 25282033 DOIRCT

Breathett K, Yee E, Pool N, et al. Association of gender and race with allocation of advanced heart failure therapies. JAMA Netw Open. 2020;3(7):e2011044.

PMID 32692366 DOIObservational

Carnethon MR, Pu J, Howard G, et al. Cardiovascular health in African Americans: a scientific statement from the American Heart Association. Circulation. 2017;136(21):e393-e423.

PMID 29061565 DOIGuideline

Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure: a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006;48(8):1527-1537.

PMID 17045884 DOIMeta-Analysis

McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008.

PMID 31535829 DOIRCT

McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004.

PMID 25176015 DOIRCT

Linhart A, Germain DP, Olivotto I, et al. An expert consensus document on the management of cardiovascular manifestations of Fabry disease. Eur J Heart Fail. 2020;22(7):1076-1096.

PMID 32640076 DOIGuideline

Birnie DH, Nery PB, Ha AC, Beanlands RS. Cardiac sarcoidosis. J Am Coll Cardiol. 2016;68(4):411-421.

PMID 27443438 DOIReview

Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11-21.

PMID 29972753 DOIRCT

Medtronic. Urgent medical device communication: Medtronic stops distribution and sale of HVAD System. U.S. Food and Drug Administration. 2021;June 3.

FDA Safety Communication Medtronic NoticeGuideline

Cleland JGF, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539-1549.

PMID 15753115 DOIRCT

Mehra MR, Naka Y, Uriel N, et al. A fully magnetically levitated circulatory pump for advanced heart failure. N Engl J Med. 2017;376(5):440-450.

PMID 28146652 DOIRCT

Chochinov HM, Kristjanson LJ, Breitbart W, et al. Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial. Lancet Oncol. 2011;12(8):753-762.

PMID 21741309 DOIRCT

Cherny NI, Radbruch L; Board of the European Association for Palliative Care. European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care. Palliat Med. 2009;23(7):581-593.

PMID 19858355 DOIGuideline

terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. © Terminal2 | terminal2.care

📝

Private Notes

Session notes — not saved to any server. Clears when you close the tab.

Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.